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Abstract 
Obesity and diabetes are metabolic syndrome associated diseases. Increased body weight has 
been noticed worldwide and the World Health Organization (WHO) considers this as an 
epidemic. Reduction in body weight helps to reduce obesity-related issues such as diabetes, 
fatty liver diseases and certain type of cancers. Stimulating the release of satiety regulation 
hormones, such as Glucagon-like peptide-1(GLP-1) has been shown to reduce food intake 
and help with weigh loss. Dietary supplementation with milk proteins has been suggested to 
be an effective approach to the prevention and treatment of obesity in humans. Other than 
milk, green tea has also been shown beneficial effect on body weight management. However, 
the precise mechanisms by which these beneficial effects are mediated are not fully 
understood. 
This research focuses on new areas for the management of obesity and discusses the 
possibility of using milk proteins and its fraction and epigallocatechin-3-gallate (EGCG) 
from green tea, to regulate appetite by stimulating the secretion of GLP-1. EGCG conjugates 
with Apo-lactoferrin (Apo-LF) were synthesized and the effect on GLP-1 studied, to 
determine if this combination might have a synergistic effect on the hormone production. 
Human colorectal (NCI-H716) cell line was used as the model cell line to study the effects of 
the test substances on GLP-1.  
The results indicate that, with β-casein showing the greatest effect on GLP-1 up regulation at 
gene and protein levels, with the least toxicity. The interaction between Apo-LF and EGCG 
in the conjugates was characterized and it was found to be via hydrogen bonding, with a 
decreased in α-helix of Apo-LF and parallel increase in β sheets.  The thermodynamic 
parameters suggest the interaction is spontaneous, involving hydrophobic forces at ambient 
temperature and electrostatic forces above 40 ºC. With regards to toxic effects on the cells, 
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the conjugates showed an increase in cell death with decrease in EGCG concentration. This 
could be due to the smaller EGCG molecule being up taken into the LF molecule at higher 
concentrations, whereas it remains on the surface of the protein at lower concentrations. 
Further, the conjugates have a higher effect on enhancing of the expression of GLP-1 
compared with pristine Apo-LF and EGCG alone and their effect on the regulation of satiety 
hormones. In conclusion, the Apo-LF-EGCG conjugates shows potential as a new therapy for 
the management of obesity, by regulation of satiety hormones. 
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Chapter1: Background and Literature review 
1.1. Introduction 
The World Health Organization (WHO) defines obesity as “abnormal or excessive fat 
accumulation that presents a risk to an individual’s health”. Obesity has become an epidemic 
and a major health problem throughout the world. According to WHO, the incidence has 
increased by two fold since 1980 especially in developed countries [1]. It is considered the 
fifth leading cause of death, resulting in at least 2.8 million adult deaths, annually [1, 2]. The 
WHO statistics also indicate that obesity increases the risk of developing chronic diseases 
such as diabetes by 40% , heart disease by 23 % and cancers between 14 – 41 % [3]. Obesity 
is also linked to high blood pressure and high cholesterol level, especially low density 
lipoprotein (LDL) and triglyceride levels and has been shown to reduce high density 
lipoprotein (HDL) levels [4]. Australia has seen a 26.8% increase in overweight and obesity 
rate in the short span between 2014 and 2015 [5] and projection indicate that incidences will 
continue rise [6].  
Energy balance is a state in which the total intake energy from food consumed is equal to the 
energy expenditure in the form of cellular metabolism and exercise, resulting in a stable body 
fat mass and controlled body weight [4, 7]. Therefore, an imbalance between energy intake 
and energy expenditure leads to weight gain and ultimately obesity [8, 9]. Changes in 
lifestyle, excessive eating of energy rich foods and a lack of exercise lead to an imbalance 
between energy intake and expenditure, thus leading to an increase in body weight and/or fat 
deposition [4, 7].  
Body mass index (BMI) is the most commonly used measurement to estimate if a person is 
overweight or obese. It is calculated by dividing the person’s weight in kilograms by the 
square of their height in meters [10-12]. Table 1.1 indicates the BMI range for each weight 
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category. It has been found that people who frequently eat food outside the house tend to 
have a much higher BMI than those who eat more at home [4] and this has been found to be 
more common in developed countries [13]. This may account for the higher obesity rates 
observed in those countries.  
Table 1.1: Body mass index categories [3]. 
However, using BMI to determine ideal bodyweight is not without its limitation. For 
example, BMI measures excess weight rather than excess body fat. Therefore, it does not 
account for muscle mass or fat distribution. In addition, body weight is influenced by other 
factors including age, gender, ethnicity, and the interactions between hormonal, genetic and 
metabolic processes, breastfeeding and economic conditions [4, 7, 14-16]. Hence, a clear 
understanding of factors that contribute to the development of obesity are critical for 
developing effective prevention and treatment strategies [11].  
Over the years, a number of potential strategies have been applied to manage and reduce 
obesity with a variety of diets and pharmacological agents. The most common strategy 
employed to prevent obesity and control body weight is increasing the expenditure of energy, 
resulting in weight loss. Using nutritional information, following a healthy diet and a 
consistent physical activities regimen are the first steps in the management of obesity [4, 11, 
17]. A complementary approach to achieve weight loss is using weight loss drugs or 
“pharmacotherapy”, some of which have been approved by the Food and Drugs 
Administration (FDA), such as Orlistat (Xenical) and sibutramine “Meridia” [11, 18]. 
Category BMI 
Under weight <18.5 
Normal 18.5 – 24.9 
Overweight 25.0 – 29.9 
Obese class 1 30.0 – 34.9 
Obese class 2 35.0 – 39.9 
Obese class 3 ≥ 40.0 
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However, the usage of these drugs is associated with a range of side effects such as increased 
blood pressure, increased heart rate and vitamin A and E deficiency [11, 17]. Bariatric 
surgery is considered to be a last resort solution for patients who have a BMI greater than 39. 
This kind of surgery is performed on the stomach and/ or intestine to reduce food intake, 
which promotes weight loss and reduces health problems such as Type 2 diabetes [11, 17]. 
Since this invasive surgical approach has many disadvantages, such as adverse events and 
high costs, the modulation of hunger and satiety regulation hormones using dietary 
approaches is a safer method to improve metabolic functions and regulate body weight [19].  
1.2. Appetite regulation along the gut-brain axis 
The gastrointestinal tract (GI) is the first organ system to encounter nutrients ingested in 
food. In addition, the brain and adipose tissue also play a vital role in maintaining body 
weight [20]. It is important to understand the mechanisms of regulating food intake and body 
weight to develop effective treatments for control of obesity and associated disorders [20]. 
What, when and how much people eat in a day is regulated by a series of signals i.e. 
hormones, that are produced from the GI tract in response to food which has been consumed 
[21]. Food provides our body with energy in the form of calories that comes from 
macronutrients (protein, fat and carbohydrate) that are essential for building cellular 
structures and maintaining body functions.  
Appetite and satiety are influenced by hormonal and nervous signals that control eating 
behavior. The most common definition of appetite is the demand to eat food and this causes 
hunger. In some cases, appetite is related to individual behavior. For example, feeling of 
stress causes increased appetite resulting in increased food intake. However, the demand to 
eat is decreased in individuals with anorexia [22, 23].  
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The three main types of signals that influence food intake are: 
(i). Satiety signals begin with an interaction between ingested nutrients and the GI tract. GI 
track hormones such as peptide YY (PYY), glucagon-like peptide-1 (GLP-1), pancreatic 
polypeptide (PP) and cholesystokinin (CCK) constitute satiety signals. These are responsible 
for maintaining meal size and symmetry with energy expenditure, thereby helping to regulate 
short-term appetite [24].  
(ii). Adiposity signals are hormones secreted directly into the blood in proportions dependent 
on the amount of stored body fat. The two adiposity signals are insulin and leptin and they 
help to regulate long-term appetite [24]. Insulin is secreted from pancreatic β–cells to regulate 
glucose levels and leptin, which is secreted from fat cells in direct proportion to the amount 
of stored fat [24]. There is an inverse relationship between insulin or leptin levels and food 
intake. Increased levels of these hormones reduces food intake and helps to lose weight 
through increased energy expenditure [25, 26], in what is referred to as a catabolic response. 
In contrast, an anabolic response leads to increased body weight by increased food intake and 
reduced energy expenditure. Hence, in obese people, insulin is secreted at higher level 
compared to underweight people, since these hormones are released into the blood stream in 
proportion to body fat mass to inhibit food intake. Figure 1.1 provides an illustration of the 
regulation of long and short-term appetite by the satiety and adiposity signals. It illustrates 
the long-term energy balance controlled by adipose tissue, leptin and insulin from the 
pancreas, whereas the short term energy balance is via satiety hormones released from the gut 
to regulate food intake and improve the feeling of satiety. If the level of leptin or insulin 
signal is low, the individual become obese [25, 26]. 
(iii). the central effectors include the hypothalamus and the hindbrain. The hypothalamus 
contains the arcuate nucleus, within which are two groups of neuronal populations. One 
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group residing in the medical arcuate nucleus can stimulate food intake, while the other is 
found in the pro-opiomelanocortin (POMC) and can inhibit food intake. A balance between 
the activities of these two nuclei is essential for regulation of body weight. The hindbrain 
controls satiety through the nucleus of the solitary tract (NTS) and the area postrema, which 
are reciprocally connected to the two hypothalamic nuclei [27]. 
Figure 1.1: Schematic representation of the regulation of long and short - term energy balance adopted 
from Cummings and Shannon [26]. 
The above two types of signals work in conjunction with the central effectors to regulate 
satiety, energy balance and body weight reduction. For example, leptin can directly act on the 
arcuate nucleus of the hypothalamus, which can either stimulate or inhibit food intake. 
Similarly, the NTS in the hindbrain expresses GLP receptors (GLP-1R), and is directly 
influenced by GLP-1. Since the NTS is connected to the hypothalamic nuclei, it plays an 
important role in appetite regulation. These regions of the brain also control emotional, social 
and learned behavior, hence these can also impact energy balance and body weight [27]. 
Green = increased. 
Red = decreased  
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1.3. Appetite controls biological responses 
Negative energy intake, continued increases in the rate of energy expenditure, as well as 
maximizing the satiety level are required conditions to achieve weight loss [28]. Moreover 
appetite is controlled by external (environment such as cultural and nutritional) and internal 
factors (storage, utilization of energy and physiological conditions by the brain mechanisms) 
[29]. A variety of physiological and social factors also influence appetite including age, 
bodyweight, sex, smoking, alcohol consumption, physical activity, cold and heat [25, 30]. 
The bio-behavioral control system of appetite can be presented in three main processes. 
Firstly, psychological events including hunger perception, cravings and hedonic sensations. 
Behavioral operations include meals, snacks and macronutrient intakes. Lastly, level of 
peripheral physiology, metabolic events, level of neurotransmitter and metabolic interactions 
in the brain [31]. Hence, it is important to understand the differences between hunger, satiety 
and satiation concepts to determine their effects on controlling body weight [29].  
Satiation and satiety are two important concepts for controlling food intake. Satiation is a 
feeling of fullness and a sense of satisfaction, signaling the individual to cease eating. 
Satiation is intra-meal factor to reduce hunger and meal size; therefore, it influences directly 
on the energy consumed from that meal. This mechanism is a result of nervous and hormonal 
signals sent from the gut [31-33]. It is a short term phenomenon which starts early during 
meal consumption and ends when eating finishes [34].  
In contrast, satiety is a biological response in which the sensation of hunger between meals is 
inhibited so people do not eat for a while [31-33]. It is an inter-meal factor developed after 
food is digested. Biological responses include stomach distension, gastric emptying rate, and 
release of pancreatic and gut hormones. Increasing the concentration of glucose, amino acids 
and fatty acids will helps in releasing of satiety hormones [31]. 
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Characterization of a homeostatic system is an important approach for the treatment of 
obesity has been discovered [35]. Hunger signals initiate eating and satiety signals inhibit 
appetite for a period [31]. Hunger is a sensation, which represents a physiological need to eat 
and usually begins when blood sugar levels results in the motivation to eat food. The 
biological relationship between leptin and ghrelin hormone levels resulting in the motivation 
to eat food. Decreasing in leptin levels in blood plasma reduceses motivation to eat. A 
significant drop in the leptin levels causes the release of ghrelin hormone, which in turn 
reinitiates the feeling of hunger [36-38].  
Taken together, these mechanisms help the human body to maintain body weight over time 
and act against starvation, preventing the development of obesity. 
1.4. Gastrointestinal (GI) track hormones in appetite control 
The GI tract is known as the largest endocrine organ in the human body [18, 39]. It releases 
more than 20 hormones to enhance the process of digestion and absorption of nutrients in the 
human gut. In addition to the direct impact these hormones have on hypothalamic and 
brainstem centers for appetite control, they also act as  inhibitors of gastric emptying to 
decrease energy intake [39]. Figure 1.2 illustrates gut hormones and their functions, effects 
and where they are produce in human body.  
Incretins are hormones that are released from the GI tract into the blood stream in the 
presence of ingested nutrients such as fats, proteins and carbohydrate [40]. These hormones 
can be classified as orexigenic (hunger hormones) and anorexigenic (satiety hormones or 
incretins). Anorexigenic hormones include peptide YY (PYY), glucagon-like peptide-1 
(GLP-1), pancreatic polypeptide (PP) and cholesystokinin (CCK) [16, 41]. In the last two 
decades, anorexigenic hormones and their contribution to increasing the feeling of satiety 
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have taken a prominent place in scientific research.  Most of this attention is focused on 
signals that improve the satiation feeling to control body weight [27, 39, 42, 43]. 
Figure 1.2: Gut peptides localization and their functions. (Adopted from Murphy and Bloom [44].) * 
Central nervous system 
1.4.1. Hormonal regulation of food intake  
Ghrelin and leptin are two hormones that play a vital role in energy balance. Leptin has its 
effect on the long-term regulation of energy by suppressing food intake. Whereas ghrelin 
known as a fast acting hormone, plays a vital role in initiating feeling of eat. Increasing 
number of obese people, understanding the mechanisms of leptin and ghrelin hormones and 
their inﬂuences on energy balance have been intensive research.  
1.4.1.1. Ghrelin 
Ghrelin is a hormone produced mainly in the stomach, from neuroendocrine cells (ghrelin 
cells) and to a lesser extent, in some areas of the brain such as hypothalamus, hippocampus, 
and cortex. It was discovered in 1999 [45] and  has a unique structure that comprises 28 
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amino-acids [38, 46]. It plays a key role in meal initiation [38], stimulates appetite, controls 
gastric motility, influences pancreatic function, impacts sleeping behavior and modulates the 
immune system [36, 46]. Ghrelin is at higher concentrations before meals, at night and during 
times of fasting. It then leads to the beginning of the meal and it is rapidly inhibited after food 
within 1 hour of meal consumption.  Therefore, it leads to progressive increase in the 
regulation of hormones just before the next meal [46, 47]. Higher plasma ghrelin level is 
associated with early obesity, due to its role in the stimulation of hunger and increased food 
intake [38, 48]. In 2011, higher levels of ghrelin secretion were observed in teenagers with a 
greater food intake compared to lean equivalents [38]. Action of ghrelin on eating behavior is 
controlled by regions in hypothalamus of the brain [47]. Ghrelin has a variety of metabolic 
functions and is considered a fast-acting hormone, responsible for meal-initiation, while 
leptin is responsible for suppressing food intake and long-term regulation [49]. 
1.4.1.2. Leptin 
Leptin is a hormone secreted by adipocytes, the placenta and the gastric fundic mucosa in the 
stomach [50, 51], and is 66 amino acids in length [49]. The obese gene (OB), responsible for 
the production of leptin was discovered in 1994 by Zhang,et al. [52]. It plays an important 
role in the regulation of food intake and energy expenditure to control and mange body 
weight [53]. It acts through two main receptors, leptin receptor (LEPR) or OB receptor. 
While higher levels of leptin are observed in obese subjects, studies suggest obese individuals 
exhibit “leptin resistance”, hence there is less regulation of food intake [54]. Interestingly, 
leptin and cholecystokinin (CCK) receptors, Ob-R and CCKR, respectively are co-expressed 
on the vagal surface in the gut wall and these two hormones play similar roles in suppressing 
food intake [55, 56].  
10 
1.5. Satiety Hormones/Incretins 
1.5.1. Cholecystokinin (CCK) 
The CCK hormone is a polypeptide hormone produced by I cells. The peptides is present in 
high concentrations in the intestinal, duodenal and jejunum mucosa in the upper small 
intestine [21]. It is a gut-brain hormone that exerts a variety of physiological actions in the GI 
tract and the central nervous system through cell surface receptors [57] . The concentration of 
the CCK hormone is increased dramatically after a meal and remains elevated high for up to 
5 hours, especially after meals containing long chain fatty acids and proteins [18, 39, 58]. 
There are many different active forms of CCK which are classified depending on their amino 
acid content including CCK-5, CCK-22, CCK-8, CCK-33, CCK-39 and CCK-58. All of 
those forms are derived from 95 amino acids and CCK-8 is the most active form found in 
human brain. While CCK-58, CCK-33, CCK-22 and CCK-8 sign significantly presenting in 
human intestine [59]. The physiological actions and satiating effects of CCK are mediated 
through two main group of receptors, CCK-A (CCK-1) and CCK-B (CCK-2) [33, 42, 60]. 
Figure 1.3 illustrates the physical action of CCK hormone in human body. This hormone 
controls gall bladder contraction, slowing of gastric emptying, modulation of gastrointestinal 
motility, bile and pancreatic secretion, and regulation of appetite [58, 61]. Table 1.2 
summaries the effect of  incretins release in GI track on food intake, satiety, and satiation and 
therefore, body weight management.  
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Table 1.2: Gastrointestinal hormones known to affect food intake [18, 39]. 
GI 
Hormones 
Sites of release 
Stimulating 
factors 
Receptors 
Sites of action 
on food intake 
Role of hormone in 
BW 
GLP-1 
Distal gut (L-cells) 
of distal small and 
large intestine; 
immunoreactivity 
in hypothalamus, 
dorsovagal 
complex, pituitary 
↑Macronutrients 
↑Bariatric surgery 
↓Somatostatin 
↓Calorie restriction 
GLP-1R 
Vagus 
Brainstem 
Hypothalamus 
↑Satiation 
↑Satiety 
Potentiates insulin 
release 
Possible pathogenic role 
in obesity 
↑promotes pancreatic β-
cell growth 
inhibits gastric 
emptying 
inhibits gastric secretion 
inhibits energy intake 
effects on 
cardiovascular system 
CCK 
Proximal small 
intestine (I-cells) 
Fat and protein-rich 
chime 
↑Coffee 
↓Bile acids 
CCK-1 
↑Satiation 
Possible pathogenic role 
in obesity 
promotes gallbladder 
contraction 
increases secretion of 
pancreatic enzymes and 
bicarbonate 
GIP 
Enteroendocrine 
K-cells in
duodenum and 
proximal jejunum 
Glucose and lipids GIPR 
↑Satiation 
↑growth of the 
pancreatic β‐cell 
↑ bone formation 
↑ hypothalamus 
proliferation 
PYY 
Enteroendocrine L-
cells 
Lipids and 
carbohydrates 
GPCR 
inhibit food intake 
reduces body weight 
CCK can be inactivated by a single enzyme named tripeptidyl peptidase II (TPP2) [17]. The 
usefulness of the CCK hormone as a therapeutic agent for obesity treatment is limited. That is 
because of its short shelf life and its effect on appetite [18]. 
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Figure 1.3: Schematic functions of Cholecystokinin (CCK) 
1.5.2. Glucose-dependent insulinotropic polypeptide (GIP) 
Glucose dependent insulinotropic peptide (GIP) plays a vital role in the release of insulin 
[62]. The peptide is 42 amino acid and is secreted by enteroendocrine K-cells found 
predominantly in the duodenum and proximal jejunum. It is encoded by the proglucagon 
gene, which also codes for glucagon-like peptide-1 (GLP-1). Its function is similar to GLP-1, 
in that, an increase in GIP leads to an increase in insulin production. GIP persists in the blood 
for approximately seven minutes before it is deactivated by the endoprotease dipeptidyl 
peptidase IV (DPP‐IV) [63, 64]. In addition to its role in the regulation of body weight (Table 
1.2), GIP has additional biological actions (Figure 1.4) such as the promotion of growth of 
the pancreatic β‐cell, stimulation of adipogenesis bone formation [65] and increasing cell 
proliferation in the hypothalamus [66]. Glucose and fat were found to be the most important 
stimulators of  the  GIP hormone in human body [63] and the GIP receptors (GIPR) are found 
in several organs such as the pancreas, stomach, and small intestine. 
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Figure 1.4: Schematic functions of Glucose-dependent insulinotropic polypeptide (GIP) 
1.5.3. Peptide YY (PYY) 
Peptide YY3-36 is the main form of PYY which belong to the pancreatic polypeptide family 
[67]. It is secreted by enteroendocrine L-cells in the GI tract, practically in the ileum, colon 
and rectum and in the upper portion of the small intestine. PYY is deactivated by the  DPP-IV 
enzyme, and activated by the theneuropeptide Y (NPY) receptor family includes Y1, Y2, Y3 
Y4 and Y5. PYY has various biological functions including slow gastric emptying, 
improvement of digestive activities and nutrient absorption and regulation of insulin [68]. It 
also plays a vital role in inhibiting of food intake and reducing body weight [69]. 
PYY levels are low during fasting time and increase within 30 min after a meal [70]. Some 
studies have found that PYY 3-36 hormone is lower in obese subjects during the fasting time 
and the increase of the hormone during and after a meal is less than in non-obese subjects 
[67, 71]. Macronutrients can stimulate PYY hormone secretion but to different levels. 
Researchers have found evidences of a synergistic relationship between PYY and GLP-1, in 
which they work together to inhibit food intake (Table 1.2) [69].  
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1.5.4. Glucagon-like peptide-1(GLP-1) 
L cells are open-type epithelial cells [72], that are found in the intestinal tract, particulary in 
the small intestine and pancreas [20, 39, 73]. GLP-1 is one of the L cell hormones and is 
produced in two different forms, GLP-1 (7-37) and GLP-1 (7-36) [18, 39]. GLP-1 actions are 
controlled by the G-protein-coupled GLP-1 receptor (GLP-1R), which is found in the GI 
track, brain, heart and in pancreatic islets [74].  It contains 30 amino acids and is encoded 
produced by the proglucagon gene (GCG) [40, 75].  
The mRNA produced by the GCG is translated to a 180 amino acid preproglucagon 
sequence, which is cleaved to produce a 160 amino acid proglucagon sequence. This 
proglucagon undergoes posttranslational shortening by cleavage of the six N-terminal  amino 
acids, removal of the C-terminal glycine, and amidation of the remaining C-terminal arginine 
residue. This results in GLP-1, the hormone secreted by L-cells [75].  
After meals the concentration of GLP-1 in blood plasma rises immediately within 10 – 15 
minutes. The half-life of bioactive GLP-1 in the blood is less than 2 minutes before it is 
deactivated by dipeptidyl peptidase IV (DPP -IV) [18, 39, 40, 73, 76]. DDP -IV, also known 
as CD26, is a serine protease and cleaves proteins that contain an alanine or proline residue. 
GLP-1hormone contains an alanine residue and therefore is a substrate for DPP –IV enzyme 
and is broken down rapidly into GLP-1 (9-37) or GLP-1 (9-36) NH2 [40]. DPP -IV exists as a 
cell surface, membrane bound peptidase found in many tissues including GI track, liver, 
kidney and pancreas [77]. The presence of nutrients in the gut and their interaction with the 
microvilli are the possible reasons for the GLP-1 secretion [78].  
GLP-1 inhibits food intake and therefore regulates energy production (Table 1.2) [20, 39]. 
Figure 1.5 depicts the functions of GLP-1. In human and animal studies, GLP-1 plays a major 
role in the reduction of food and calorie intake in patients with type 2 diabetes. Recent studies 
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have shown that the levels of the GLP-1 in the blood plasma are lower in obese people, 
though the cause has not yet been identified [58, 79]. GLP-1inhibits the secretion of gastric 
acid and glucagon release from α-cells in the pancreas [53, 73] improving in pancreatic β-cell 
mass by inhibiting apoptosis [39, 76]. GLP-1 is also thought to influence learning and 
memory [80].  
Figure 1.5: Schematic representation of the functions of glucagon-like peptide-1 (GLP-1)
1.6. Incretin release as an alternative approach to obesity treatment  
Anti – obesity drugs aim to increase metabolic rate and reduce the absorption of 
macronutrients especially fats and carbohydrates [81]. However, current research interests 
revolve around controlling appetite by stimulating satiety regulation hormones such as CCK, 
PYY and GLP-1 [82, 83]. Evidence has been growing regarding gut hormones and their 
action in the treatment of obesity. Presented below is a short list of commercially available 
anti-obesity drugs that target hormone regulation.  
Exedin-4 is isolated from the venom of a lizard has been approved for type 2 diabetes due to 
its incretin-like properties [43, 84]. It is a 39 amino acids peptide that shows glucoregulatory 
activities similar to the GLP-1 hormone. It enhances insulin secretion and decrease glucagon 
secretion, and decelerates gastric emptying. In animal diabetes studies and cell lines, 
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exenatide-4 and GLP-1 have been shown to improve in β-cell function by increasing gene 
expression responsible for insulin secretion [85]. 
Human GLP-1 hormone is proving to be a promising anti-obesity drug; however, its 
consumption may cause nausea and vomiting [86]. In addition, it has been found that obese 
individuals showing decreased GLP-1 responses compared with lean controls, show no 
improvement in GLP-1 secretion after weight loss [78]. The mechanism whereby obesity 
lowers GLP-1 secretion is not understood, however studies suggest it might be related to the 
insulin resistance that accompanies weight gain. Therefore, regulation of gut hormones may 
be effective in treating obesity, with fewer side effects and reduced weight regain after 
discontinuation of the treatment [81, 87]. Other incretin mimetic drugs which can have same 
effect as incretin that the body usually produces naturally are listed below:  
DPP-4 inhibitor is prescribed to individuals who suffer from type 2 diabetes. The drug 
regulates blood sugar levels after eating. After a meal, GLP-1 and GIP hormones are released 
to increase insulin secretion, however they are quickly degraded by DPP-4, and have a short 
circulation period. DPP-4 inhibitors, such as Sitagliptin and Saxagliptin block the DPP-4 
receptors, thereby preventing the release of DPP-4 and hence preventing cleavage of GLP-1 
and GIP [88, 89]. Sitagliptin (known commercially as Januvia), has been approved by the 
Food and Drug Administration (FDA) and is meant mainly for diabetic patients. It is 
predominantly used to treat diabetic patients. It is prescribed in combination with insulin 
releasing pills and insulin injections. However, sitagliptin commonly produce side effect in 
users such as sore throat, runny nose and low blood sugar, especially when it is taken with 
insulin releasing pills and insulin [88, 89]. 
GLP-1 Analogs are injected therapeutics which control blood sugar levels after eating. GLP- 
1 analogs act like GLP-1 hormone and were developed to resist cleaving by DPP-4 which 
allows long lasting effects of GLP-1 [88, 89]. 
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1.7. Effect of dietary proteins on incretins 
Significant changes have been shown in hormone concentrations after high protein meals 
[90]. Studies indicate that protein induced satiety occurs through (1) increased in the 
concentration of satiety regulation hormones including GLP-1, CCK, PYY or reduction in 
ghrelin hormone, (2) increased energy expenditure as a result of increase in metabolite 
reactions, and (3) increased gluconeogenesis. Gluconeogenesis is defined as the synthesis of 
glucose from non-carbohydrate source.  
Proteins form an essential component in the human body and play a role in the bodies 
structure, repair and functional activities. Amino acid units combine to form protein and to 
metabolic compounds [91]. Consumption of proteins increases satiety, regulates satiety 
hormones and decreases food intake and appetite in humans [92-97]. A high protein meal 
helps to delay the consumption of the next meal by at least 60 min, as  compared with 34 min 
for carbohydrate and fat [98]. A number of studies have been conducted to examine the 
effects of proteins on hunger, satiety and food intake. For example, amount of proteins play a 
vital role on the duration of satiety and delay feeling of hunger more than fat or carbohydrate 
[91, 99, 100]. High protein diets have shown increased levels of satiety within a range of 25 
% to 81 % with significant energy intake reduction. Moreover, the source of proteins may 
play an important role in satiety. For example, meat, egg, soy and milk proteins exert 
different effects on satiety. [101-103]. Hence, there is a need to understand the effect of 
protein fractions, to minimize the side effects, while allowing increased satiety regulation. 
Researchers have shown considerable interest in the use of dairy proteins to improve 
metabolic health with greater impact on satiety [28, 104]. Milk proteins and their fractions 
have been reported to exert differential effects on GI hormone secretion and appetite [90, 
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105-109]. They have functional properties for controlling body weight, and associated with a
decreased risk of developing metabolic syndrome diseases [91, 95, 110]. 
1.8. Milk composition 
In the last two decades milk and individual milk components have gained considerable 
attention, in terms of their satiation effect [107, 111]. Milk is secreted in  the mammary 
glands of mammals by epithelial cells which line the mammary alveoli and is stored in the 
alveolar lumina adjacent to those cells [112, 113]. It  is a nutrient rich source of high-quality 
proteins and fats [114]. Therefore, it is considered as an essential part of human diet. In 
addition, it is inexpensive and readily available for consumption [115, 116]. The major 
protein fractions of milk; casein and whey (Figure 1.6), have been reported to increase satiety 
and reduce food intake by improving secretion of gastrointestinal hormones. In addition, milk 
helps glycemic control through insulinotrophic mechanisms [110, 111, 117, 118]. However, 
the exact mechanism by which milk contributes to the regulation of satiety, food intake and 
blood glucose is not well-understood.  
1.6: Milk composition and its molecular protein includes. α, β and ҡ- casein α and  β- lactalbumin , 
Lactoferrin (LF) and Bovine serum albumin (BSA). α= alpha ; β = beta ; ҡ = kappa. 
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The composition of milk varies depending upon the breed of dairy animals, stages of 
lactation and nutritional status [119]. Milk is composed of three main components including 
fat, carbohydrates and protein and its molecular protein constituents (Figure 1.6) [120]. In 
addition, it contains significant nutrients which contribute to the required intake of minerals 
and vitamins such as calcium, magnesium, selenium, riboflavin, vitamin B12 and pantothenic 
acid [121].  
1.8.1.  Milk fat and sugar 
Milk is an oil- in water emulsion [114] containing riacylglycerols, phospholipids, sterols and 
traces of fatty acids. It contains 65% saturated, 32% monounsaturated and 3% 
polyunsaturated fatty acids as well as fat soluble vitamins A, D, E, and K [114]. It also 
contains about 4.5 – 4.9 % of lactose , which is the carbohydrate source consisting of two 
sugars; glucose and galactose, that provides 4 calories/g when metabolized by lactase [112, 
122].   
1.8.2. Milk proteins 
The protein content of milk is approximately 3.3% of casein and whey proteins (Figure 1.6). 
Whey and casein are classified as high quality proteins based on human amino acid 
requirements, digestibility and their bioavailability functions. They have functional properties 
for the control of food intake and glycaemia [123, 124]. Furthermore, milk proteins are 
considered an important source of bioactive peptides which have been found in milk protein 
hydrolyses and fermented dairy products. Milk proteins contain more than 26 bioactive 
peptides which have been isolated from either casein or whey protein such as β -
casomorphin-5, α-Casein-exorphin, α-Lactorphin, Lactokinin, Immunopeptide and β–
lactorphin. The amino acid sequence of the individual peptides ultimately determines their 
function of those peptide [124]. Various physiological activities have been defined against 
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pathogens and illnesses for milk bioactive peptides such as anti-oxidative antimicrobial 
proteins and anti-microbial properties [124, 125].   
1.8.3. Milk vitamins and minerals 
Dairy products are significant source of micronutrients. They provide more than 10% of 
nutrients required by humans including vitamins A, B12, calcium, phosphorus, potassium and 
zinc [126]. The roles of these minerals have been studied in the treatment of metabolic 
disorders. For instance, milk contains high levels of calcium which plays a vital role in body 
weight regulation [127] and may also improve lipid profiles [128]. 
1.9. Milk proteins and its role in inducing satiety 
Dairy consumption can be beneficial in achieving lower body weight and decreasing the risk 
of developing hyperglycemia and diabetes [108], decreasing the prevalence of metabolic 
disorders [94, 129], and increasing energy expenditure [94]. Milk protein fractions lead to 
decreased food intake in the short term by regulating food intake hormones stimulating 
glucose utilization [90, 108, 117]. A high protein breakfast which contains 58% of total 
energy (mainly dairy products), increase GLP-1 concentrations over 3 hours compared with 
high carbohydrate breakfast that contains only 19% of protein [107].  
While the effect of whey and casein has been addressed particularly in satiating [130], it is 
not clear which component has a better effect [99, 107] . One study showed similar effects on 
satiety and food intake between whey proteins and caseins [92], while other studies found 
that whey protein has a stronger effect on hunger and food intake compared to casein, soy 
and egg albumin [90, 94, 107, 129]. They suggested that the increased effect observed for 
whey proteins was due to the high concentration of branch chain amino acids (BCAAs) 
compared to casein, which leads to an increase in plasma amino acids and levels of plasma 
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incretins [90, 94, 107, 129]. Similar results have been found relating to the effect of whey 
protein on the energy intake; where the mean energy intake was significantly lower for whey 
protein consumption compared with other sources of proteins, including  tuna, egg and turkey 
[103]. A recent study involving whey proteins showed reduction in hunger and food intake 
compared to casein. The authors showed that a small amount of whey proteins, especially 
whey proteins isolate, could increase the satiation feeling and prevent the onset of type 2 
diabetes mellitus [94]. Consuming 30 g and / or 15 – 20 % of whey protein can reduce food 
intake for 30 minutes, and that is more than any other sources of protein [131]. Also, diet 
supplement with whey protein led to increased feeling of satiation compared with 
carbohydrates and soy proteins in overweight and obese people [132]. Interestingly, skim 
milk, which contains both proteins – casein and whey, has been found to decrease food intake 
more than the individual proteins [133].   
 With regards to hormone regulation, whey proteins have a stronger response of GLP-1 in 
humans, compared to casein and soy [111]. A human trial by Bowen et al in 2007, found that 
50 g of whey protein resulted in a prolonged suppression of ghrelin and raised GLP-1 and 
CCK levels without changing food intake [105]. The concentration of CCK hormone in 
plasma increased significantly after a whey protein meal within 15 – 20 min and remained 
high for more than 3 h [90, 132]. On the other hand, CCK hormone was higher after casein 
consumption in one study [90]. Plasma GLP-1 concentrations fell substantially after 2 h of 
consumption of whey, whey hydrolyses and casein hydrolyses solutions, but increased 
continually with the casein solution. This effect is due to the slow rate of casein digestion 
[102, 104, 107, 111]. In comparison, casein contains peptides such as casomorphins, which 
help reduce gastrointestinal motility, gradually increasing amino acid concentrations in 
plasma and contribute to satiety  [134]. However, based on protein absorption rates, there is 
no clear evidence to suggest that one of the milk proteins is more satiating than the other 
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[102]. In fact, it has potential impact on increased digestion and absorption rate of the protein 
[102]. Calbet and Holst in 2004 have confirmed that intact casein and whey proteins were 
absorbed at lower rate than hydrolyzed. The rate of GLP-1 and PPY responses in blood 
plasma was higher with hydrolyzed milk proteins solution [135]. Effect of hydrolyzed milk 
proteins were examined on appetite regulation. Hydrolyzed whey protein had less effect on 
appetite regulation [136].   
It has been also been suggested that incomplete proteins (which lacks one or more essential 
amino acids) might be more satiating and reduce food intake than complete proteins. The 
effect of whey and casein has been compared with incomplete proteins on satiety and 
incomplete proteins have been found to increase satiety more than whey and casein. Diets 
with low levels of essential amino acids will decrease the concentration of those amino acids 
in plasma. As a result, the brain will reject consumption of unbalanced diets therefore 
initiating the feeling of hunger [137].  
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Chapter 2: Hypotheses and objects 
2.1. Rationale of thesis 
Hence, there are no sufficient studies applied on the effect of milk protein and its fraction on 
the regulation of satiety hormone. Summary of in vitro studies are provided below which 
showed the effect of different source of proteins on satiety regulation hormones. Table 2.1 
provides a brief outline of the effect of different proteins on satiety hormones released.  
Table 2.1: Effect of different proteins on release of satiety hormones release 
Aims of study In vitro cell line 
Effect of reagent on 
satiety hormones 
References 
Effect of glutamine on 
the GLP-1-secreting cell 
line 
GLUTag. 
Increased GLP-1 released 
more glucose. 
Reimann, F., et al. 
(2004).[1] 
Effect by which milk 
proteins including 
leucine, isoleucine, 
valine, skim milk, 
casein, and whey 
improve GLP-1 release 
NCI-H716, in dose 
response 0.5%, 1.0%, 
2.0%, and 3.0%. 
Leucine, isoleucine, skim 
milk, and casein 
stimulated GLP-1 release. 
Chen, Q. and R. A. 
Reimer (2009).[2] 
Effect of olive leaf 
extract, glutamine, 
chlorogenic acid α-
casein & β-casein 
STC-1 
All test reagents except α-
casein showed significant 
increase in GLP-1 
secretion. 
Rafferty, E. P., et al. 
(2011).[3] 
Investigated which 
dietary proteins, 
hydrolysates, or 
synthetic-peptides most 
impact on the secretion 
of CCK and GLP-1 
STC-1 
Casein and whey showed 
strongest effects on CCK 
release, whereas casein 
affected GLP-1  
Geraedts, M. C., et al. 
(2011).[4] 
Based on the review of the literature presented in Chapter 1, it is evident that milk proteins 
have a promising effect on increasing satiety, however, lactose intolerance, increased blood 
lipids and cardiovascular disease risks and kidney disease resulting from high calcium 
content in milk can pose issues for the use of milk proteins to regulate body weight. Hence, 
this thesis will aim to identify which milk protein and its fraction would have the most effect 
on satiety hormone regulation. Further, this project will explore the combined delivery of 
milk protein and polyphenols from green tea, in comparison to the individual components on 
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satiety hormone regulation. This protein-polyphenol conjugate could provide a new 
promising approach to be used as anti-obesity treatment. 
This thesis will aim to answer the following research questions 
1. Do milk proteins have the ability to influence the production of GLP 1, the major GI track 
satiety regulating hormone? 
2. Is there a difference in the ability of different milk proteins in influencing regulation and 
secretion of GLP-1? 
3. What are the mechanisms by which milk proteins influence the secretion of satiety 
hormones? 
4. Can milk proteins be used as a platform to deliver bioactive compounds for GLP-1 
secretion? 
2.2. Research aims 
In order to answer these research questions through in vitro study, this project will comprise 
of the following four aims: 
Aim 1: Identification of milk proteins and fractions that are able to stimulate the secretion of 
GLP-1.  
Aim 2: Compare efficacy of selected (promising) whey or casein proteins / fractions to 
stimulate the secretion of GLP-1.  
Aim 3: Elucidation of molecular mechanisms by which milk protein influence the secretion 
of GLP-1. 
Aim 4: Synthesis & characterisation of protein–polyphenol conjugate and its effect on the 
regulation of GLP-1 hormone.as well as, to elucidate its potential as dietary supplementation 
to prevent obesity and control body weight.    
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2.3. Outline of thesis 
Chapter 1 provides an introduction and review of existing literature on the use of milk and 
milk proteins as an approach to control body weight and anti-obesity treatment. It also 
provides an explanation of the regulation of satiety hormones in the body and how this can 
provide a solution to formulate diet supplements for controlling body weight. 
Chapter 2 summarize of project background and aims 
Chapter 3 gives details of the methodology employed in this thesis, including synthesis and 
characterisation techniques and provides an explanation of the in vitro assays used to study 
satiety hormone regulation. 
Chapter 4 deals with identifying the milk protein that has the best effect in regulation of 
GLP-1 and the molecular mechanism by which this occurs, in human intestinal cells.  
Chapter 5 investigates the formation of a conjugate between a milk protein and a polyphenol 
from green tea; physio-chemical characterisation of this conjugate which will be used to 
monitor satiety hormone regulation in human cells. 
Chapter 6 explores the in vitro effects of the milk protein-polyphenol conjugate on human 
intestinal cells and the use of this conjugate as a platform to deliver bioactive compounds to 
enhance satiety hormone secretion. 
Chapter 7 provides a summary of findings in the conclusion and future direction work 
possible, based on the results obtained from this thesis.     
2.4. References 
1. Reimann, F., et al., Glutamine potently stimulates glucagon-like peptide-1 secretion from
GLUTag cells. Diabetologia, 2004. 47(9): p. 1592-601. 
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Chapter 3: Materials and methods 
3.1. Bio-chemicals and reagents 
Casein and whey proteins were gifts from Fonterra Dairy (Australia). Purified (Apo-LF), 
saturated (LF SAT) and semi saturated (LF SEMI) lactoferrin samples were gifts from Tatura 
Milk Industries Ltd., a subsidiary of Bega Cheese, (Australia). (−)-Epigallocatechin gallate 
(EGCG) (purity ≥95.0%), gallic acid (GA, 98%), Sodium phosphate dibasic and Sodium 
phosphate monobasic dehydrate, Iron (III) chloride hexahydrate, 2,2′-Azino-bis (3-
ethylbenzothiazoline-6-sulfonic acid ,Pluronic F-127, Krebs ringer bicarbonate Buffer, 
Adenosine 5′-triphosphate (ATP), Ionomycin calcium salt (INO) disodium salt hydrate, 
potassium per-sulphate, (±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid and 
dialysis tubing cellulose membrane (12 kDa cut-off) were purchased from Sigma-Aldrich 
(Australia). Sodium phosphate buffer (pH 7.0) was prepared by mixing 30.5 mL of 0.2 M 
Na2HPO4 with 19.5 mL of 0.2 M NaH2PO4 and made up to a final volume of 100 mL. 
Roswell Park Memorial Institute (RPMI) 1640 medium, Dulbecco’s Modified Eagle 
(DMEM) medium, Foetal bovine serum (FBS), 1x phosphate buffered saline (PBS), - 0.53 
mM Ethylenediamine tetraacetic acid (EDTA), Geltrex™ hESC-Qualified Ready-To-Use 
Reduced Growth Factor Basement Membrane Matrix, Trizol, High-Capacity cDNA Reverse 
Transcription Kits, TaqMan fast universal PCR master mix, FAM-MGB probe/primer set for 
GLP-1 (Hs01031536_m1) and β- Actin (Hs02742610_g1), donkey anti mouse polyclonal 
antibody tagged with HRP (secondary antibody for the enzyme-linked immunosorbent assay 
(ELISA)), Hoechst 33342, gold anti-fade mounting medium and RIPA Lysis and Extraction 
Buffer were purchased from Life technologies (Australia). BCA Protein Assay Kit was 
purchased from Thermo Fisher (Australia). Anti-GLP1 antibody was purchased from 
Abacam (Australia). 16% paraformaldehyde was purchased from Electron Microscopy 
Sciences (Australia). Working solution of 4% was prepared in PBS and chilled to 4 °C right 
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before use. ELISA reagents including coating buffer, wash buffer, substrate and stop solution 
were purchased from BD Bioscience (Singapore). MilliQ water was used for all experiments. 
75 cm2 flasks, centrifuge tubes and tissue culture grade 96 well, 12 well and 6 well plates 
were purchased from Corning (Australia). Pipette tips and 1.7 mL tubes were purchased from 
Eppendorf (Australia).  
3.2. Determination of protein concentration in milk samples using BCA kit 
Protein content was determined using BCA Protein Assay Kit. This method is based on the 
reduction of Cu+2 to Cu+1 by protein in an alkaline medium. The resulting purple coloured 
solution is produced by the chelation of two molecules of bicinchoninic acid (BCA) with one 
cuprous ion [1]. The protocol was followed according to the manufacturer’s instructions. 
Briefly, a series of dilutions of known concentrations were prepared with the BSA (0-2 
mg/mL) and assayed alongside the samples (Table 3.1). 25 µL each standard or unknown 
sample in triplicate was taken in a 96 well plate.  Additional of 200 µL of the BCA Working 
Reagent (WR) was added to each well and mixed thoroughly on a plate shaker for 30 
seconds. WR was prepared by mixing 50 parts of BCA Reagent A with 1 part of BCA 
Reagent B. The plates were incubate at 37 ºC for 30 min., after which the plates were cooled 
to room temperature (RT). Absorbance at 562 nm was read using a Envision Micro plate 
reader (PerkinElmer, USA). Protein concentrations of the samples were determined using the 
linear regression equation generated from the BSA standards. 
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Table 3.1. Preparation of BSA Standards for estimation of total protein content 
No Volume of PB (µL) 
Volume of Diluent 
(µL) 
Final PB Concentration (µg/mL) 
1 100 0 2000 
2 75 25 1500 
3 50 50 1000 
4 37.50 62.5 750 
5 25 75 500 
6 12.5 87.5 250 
7 6.25 93.75 125 
8 1.25 98.75 25 
Blank 0 100 0 
3.3. Selection of in vitro cell models and cell culture conditions 
A number of cellular models of animal and human origin have been used to study the 
regulation of satiety hormones secretion, such as mouse intestine cell lines (STC-1), human 
colorectral cells (NCI-H716) and murine endocrine cells (GLUTag) [2]. Those modules have 
provided useful information regarding the signalling pathways that regulate proglucagon gene 
expression for example GLP-1 secretion [2]. GLP-1 is an incretin hormone that is released by 
enteroendocrine L cells in the gastrointestinal tract (GI). Since NCI-H716 cells have been 
extensively validated as models to investigate GLP-1 secretion [3], these cells were chosen to 
study GLP-1 expression. NCI-H716 cells release GLP-1 not only in response to nutrient 
stimulation including fatty acids, amino acids, protein hydrolysates, artificial sweeteners and 
bitter compounds, but also in response to other hormones such as insulin, leptin and selected 
neurotransmitters [4, 5]. Hence, NCI-H716 cell lines were chosen for this project, to study the 
effects of milk proteins on regulation of satiety hormones. 
3.4.  Cell culture conditions of NCI-H716 cell line 
According to ATCC product sheet, the NCI-H716 cell line was initiated from ascites fluid of 
a 33-yr-old male with poorly differentiated adenocarcinoma of the colon. This is a hypo 
triploid human cell line with a modal chromosome number of 61 occurring in 28% of cells. 
The cells will be grow in suspension in RPMI 1640 medium supplemented with 10% FBS, 
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100 units/ml penicillin, and 100 µg/ml streptomycin. Cells were maintained at 37 °C in the 
presence of 5% CO2 and 95% humidified air. Figure 3.1 depicts normal cell morphology as 
observed under a phase contrast microscope (Nikon Eclipse TS100, Nikon Corporation, 
Japan). RPMI medium was used for subculturing and maintenance of the cells in suspension. 
However, those cells change to adherent morphology and express GLP-1 only in DMEM 
media with Matrigel. Hence, to setup the experiments, cells were seeded in complete DEME 
medium into wells precoated with Matrigel [4].  
 
Figure 3.1: shows NCI-H716 human cell extensively validated as models to investigate GLP-1 secretion, 
represented at different magnifications, a: 40x ,b:100x and c: 200x 
3.5. Cell viability assay 
Measurement of in vitro cell viability has been applied further determine if test reagents show 
cytotoxic effects and to determine subtoxic concentrations for gene and protein expression 
assays. Different tetrazolium compounds have been used to detect cell viability such as MTT, 
MTS, XTT, and WST-1.  3-4, 5-dimethylthiazolyl-2-2, 5-diphenyltetrazolium bromide 
(MTT) assay is a popular method to examine cell viability and was chosen for this project. It 
was the first cell viability assay developed for a 96-well plate [6]. MTT reagent enters the 
cells and passes into the mitochondria where it produces purple formazan crytals. Figure 3.2 
represents the chemical reaction involved in this conversion. The quantity of formazan refers 
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to the number of live cells and is measured by absorbance readings at 570 nm Envision Micro 
plate reader (PerkinElmer, USA) [6]. 
Figure 3.2: Reduction of MTT to purple formazan crystal in metabolically live cells by enzymatic 
reduction of a yellow 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide salt (MTT). 
Cells were seeded at a density of 5×104 cells/well in 96 well culture plates in DMEM 
complete media and incubated at 37 °C in the presence of 5% CO2 and 95% humidified air. 
After 24 h, the test agents at required sub-concentrations starts from 5% for each component 
added in complete media. After 24 h, 0.5 mg/mL MTT solution (MTT stock solution was 5 
mg / mL were dissolved in PBS) was added in serum free media and incubated for 4 h at 37 
°C in the presence of 5% CO2 and 95% humidified air. At the end of incubation period, the 
formazan crystals generated by live cells were dissolved in 100 µL of acidified isopropanol in 
each well and absorbance measured at 570 nm. The results are presented as percentage 
viability, taking average of three independent experiments and each experiment contained 
three replicates. The percentage viability of cells was determined against cell free control. In 
order to remove background absorbance and to make sure that test sustained did not interact 
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with MTT, cell free control at each concentration was used. The absorbance reading from 
those wells was subtracted before the final calculation of cell percentage viability.  
3.6. Gene expression assay 
Gene expression involves two main processes. Starts with transcription process inside the 
nucleus where different types of RNA are produced, including messenger RNA (mRNA), 
transfer RNA (tRNA) and ribosomal RNA (rRNA). mRNA produced from the nucleus in 
preparation for protein expression, hence monitoring mRNA levels can provide information 
on the gene expression associated with a certain protein [7]. Figure 3.3 show a schematic 
diagram of gene expression production in human cells. 
In order to study regulated changes in gene expression, we need a technique to measure how 
gene activity patterns vary within an organism. Genes encode messenger ribonucleic acid  
(mRNA) which are translated into proteins, as a result gene expression can be assessed at 
either the mRNA or the protein level [8, 9]. Quantitative reverse transcription polymerase 
chain reaction (qRT- PCR) is an increasingly used powerful method because of its high 
sensitivity, and wide dynamic quantification range for the detection and quantification of 
gene expression in tissues [10, 11].  
For successful and reliable results in real-time qRT-PCR, RNA needs to be of high quality, 
and DNA-free. Hence, pure RNA is critical to all gene expression analysis techniques [12-
14]. RNA extracting techniques may work differently depending on the type of cells and 
origin of the tissue, leading to up to 10 fold variations in the total RNA yield [11, 13, 14]. For 
this study, TRIzol method was used for RNA extraction. RNA extraction using Trizol reagent 
has been proven to be an effective method for RNAs including microRNAs, piwi-associated 
RNAs, or endogeneous, small interfering RNAs [15]. Since RNA is easily degraded by 
RNases even during the RNA purification or storage [16, 17], samples were stored in TRIzol 
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at -80 °C  until the extraction process could be performed and converted to complementary 
deoxyribonucleic acid (cDNA) on the same day of extraction. 
Figure 3.3: Schematic representation of gene expression 
3.6.1. Gene expression studies 
For gene expression study, cells with total of 2×106 cells were seeded in 12 well culture 
plates coated with matrix gel in reconstituted DMEM medium. After 24 h, cells were treated 
with media containing different concentrations of test reagents and 0.2% bovine serum 
albumin (BSA) instead of FBS. 100 µM glucose was used as positive control [18]. After 18 h 
of treatment, TRIzol was added to the cells and samples were stored in 1.7mL RNase/DNase 
free tubes at -80 °C.  
3.6.2. Ribonucleic acid (RNA) isolation 
After Trizol was added to samples, 200 µL of chloroform per 1 mL of TRIZOL was added to cause 
phase separation where DNA remains in the interface, and RNA remains in the aqueous phase. Tubes 
were mixed vigorously. Samples then were centrifuged at 12,000 x g for 15 mins at 4° C. After 
centrifugation, upper aqueous phase containing RNA was transferred carefully into new tube. 500 µL 
of isopropyl alcohol was added per 1 mL of TRIZOL precipitation of nucleic acid. Samples were 
then incubated at room temperature for 10 mins and centrifuged at 12,000 x g for 15 mines at 4° C. 
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Supernatant was completely discard, and RNA pellet was washed with 75% ethanol, Samples were 
vortexes and centrifuge at 12,000 x g for 15 mins at 4 °C. All leftover ethanol was removed  by air-
dry RNA pellet for no more than 5mins. RNA pallet was dissolved in nuclease free water. Dissolved 
RNA samples was quantify using Nano-Q. The yield was determined based on A260/A280 
ratio. 
3.6.3. Complementary deoxyribonucleic acid (cDNA) synthesis 
After extracting RNA, 2 µg of total RNA was reverse-transcribed using High-Capacity 
cDNA Reverse Transcription Kit. The procedure was followed as per manufacturer’s 
instructions. The master mix was prepared as shown in Table 3.2. Thermal cycling was 
performed on a BioRad T-100 thermal cycler and the running conditions are displayed in 
Table 3.3. Samples were stored at -20 °C. 
Table 3.2: Volume of component to prepare 2x RT Master Mix per 20 μL reaction. 
Component Volume (µL) 
2.0 
0.8 
2.0 
1.0 
4.2 
10.0 
Table 3.3: Thermal cycle conditions optimized for High-Capacity cDNA Reverse Transcription Kits. 
Step 1 Step 2 Step 3 Step 4 
Temperature (°C) 25 37 85 4 
Time (mins) 10 120 5 ∞ 
3.6.4. Real-time quantitative polymerase chain reaction (qPCR) 
cDNA was subjected qPCR to analyse the expression of the target genes, GLP-1 and β-actin 
was selected as the housekeeping gene. GLP-1 is produced by proglucagon gene in human 
body (Chapter 1 section 1.5.4), GCG (glucagon) is the Taqman prime used to study GLP-1 
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gene expression [19]. The reaction mix was set up as shown in Table 3.4, as per 
manufacturer’s instructions. Samples were run on a 7500 Fast Applied Biosystems 
instrument. Samples were held at 50 °C for 2 mins, 95 °C for 10 mins, followed by 40 cycles 
of 95 °C for 15 mins and 60 °C for 1 minute. The threshold cycle values (Ct) were 
determined at the same fluorescence threshold line for each gene. The fold change in target 
gene relative to the housekeeping gene and the untreated samples are expressed as fold 
change of delta delta threshold cycle (∆∆Ct), taking average of three independent 
experiments and each experiment contained three replicates.  
Table 3.4: qPCR samples preparation 
qPCR µL/reaction µL per well 
2x TaqMan gene expression master mix 5 
5.5 µL 
20x TaqMan gene expression assay mix 0.5 
cDNA sample 2.5 
4.5 µL 
Ultrapure RNase DNase free H2O 2 
3.7. Enzyme-linked immunosorbent assay (ELISA) 
For protein expression study, protocol was adopt from Chen and Reimer [4] with minor 
modifications. In brief, cells were seeded at a total of 2×106 cells/well in 12 well culture 
plates coated with matrix gel in reconstituted DMEM medium. After 24 h, cells were treated 
for 3 h with media containing different concentrations of test reagents and 0.2% BSA. After 3 
h, culture supernatant was saved for extracellular release and cells were washed with cold 
PBS twice and 500 µL of radioimmunoprecipitation assay buffer (RIPA) was added to cells 
with the addition of 50 mg/L of phenylmethylsulfonyl fluoride and 34 mg/L of diprotin A. 
Cells were incubated for 15 mins on ice. Cells were then collected and centrifuged at 14,000 
× g for 15 minutes to pellet the cell debris. Supernatant were frozen at -80 °C and dried using 
an OPERON (Gimpo, Korea) freeze dryer -55 °C to obtain a concentrate protein content 
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powder. The culture supernatant collected for extracellular protein levels was also 
supplemented with 50 mg/L of phenylmethylsulfonyl fluoride and 34 mg/L of diprotin A. 
Protein concentrations were determined using BCA kit as described in Section 2.2. GLP-1 
protein standards concentration was 1mg/mL and was dissolved in coating buffer. Wells were 
coated and allowed to incubate overnight at 4 °C. Uncoated samples were discarded and 
wells were washed with 1X washing buffer. Wells were blocked with 2% of BSA (blocking 
buffer) to prevent non-specific binding of antibodies and allowed to incubate for 45 mins at 
room temperature (RT). Blocking buffer was discarded and 1:40,000 dilution  of Anti-GLP1 
antibody-10 primary antibody was added to each well and incubated for 1 h at RT. Plate was 
washed 5 times for 30 seconds each. Secondary antibody of donkey anti mouse polyclonal 
antibody tagged with Alexa Fluor® 488 was added (1:10,000 dilution) to each well, and plate 
was incubated for 45 mins at RT and in the dark. Secondary antibody was discarded and the 
plate was washed 5 times with wash buffer for 30 seconds. 100 µL of the substrate was added 
and incubated for 25 mins in the dark. Finally, 20 µL of stop solution was added and 
absorbance read immediately at 450 nm. 
3.7.1. Confocal microscopy 
The protocol was adapted from Anna L.Gillespie,et al. [20] with minor modifications. Total 
of 2x106 cells were seeded per well in 6 well culture plates coated with matrix gel in 
reconstituted DMEM medium. Cells were treated as described in Section 3.7. After treatment, 
media was removed and cells fixed with 4% cold paraformaldehyde (PFA) for 10 mins at 
room temperature. Cells were washed three times with PBS and stored in PBS at 4 °C until 
staining could be performed.  
For the staining, the PBS was removed and cells were permeabilised with 0.02% Triton X-
100 in PBS for 90 seconds at RT. Cells were washed once with PBS, followed by blocking 
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with 2% BSA in PBS for 30 min. Cells were then incubated with 1:200 dilution of GLP-1 
primary antibody in blocking buffer for 1 h. After washing three times with PBS, cells were 
incubated with 1:500 dilution of secondary antibody (donkey anti mouse polyclonal 
antibody) tagged with Alexa Fluor® 488  in blocking buffer, for 1 h, in the dark. Cells were 
washed 5 times in PBS, followed by staining with Hoechst 33342 (2μg/mL in PBS) for 10 
mins. After the final three PBS washes, cells were mounted on to glass slides using ProLong 
gold antifade mounting medium and imaged on a N – STORM SuperResolution/Confocal 
microscope (Nikon-Japan). Images were obtained using the NIS Elements 4.0 software. 
3.7.2. Flow Cytometry 
Flow cytometry has been developed in the late 1960s, and is become a popular analytical 
technique for cell biology. It utilizes light to count and profile cells in a heterogenous fluid 
mixture [21]. The histogram plots a single parameter (horizontal axis) against the number of 
events detected (vertical axis) [21, 22].  
For flow cytometry analysis, a total of 2x106 cells were seeded per well in 6 well culture 
plates coated with matrix gel in reconstituted DMEM medium. Cells were treated as 
described in Section 2.7. Cells were detached from the wells using 1 mL of trypsin-EDTA for 
5 mins. The trypsin-EDTA was neutralised using complete media and cells were centrifuged 
at 1000 rpm for 5 mins. Media was removed and cells fixed with 4% of for 10 mins at room 
temperature. Cells were washed in PBS and stored in PBS at 4 °C until staining could be 
performed. For the staining, the PBS was removed and cells were permeabilised with 0.02% 
Triton X-100 in PBS for 90 seconds at room temperature. Again, cells were washed 4 times 
with PBS and 1 µL/mL GLP-1 polyclonal primary antibody was added in 0.1% Triton 
followed by incubation for 1 h at RT.  Cells were washed (×4) with PBS by centrifugation. 
Secondary antibody of donkey anti mouse polyclonal antibody tagged with Alexa Fluor® 488  
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(1 µL/mL) was added and incubated at room temperature in the dark for 1 h. Cells were 
washed thrice  with PBS and flow cytometry analysis was performed on a BD Accuri flow 
cytometer. Forward (FFS) vs side (SSC) scatter was performed and gated to remove cell 
debris. From within the gated sample, histogram was generated from 10000 events, using the 
FL-1A (green filter) vs count. Unstained cells and cells stained with only primary and only 
secondary antibodies were used as controls. The data was analysed using FlowJo software, 
where fluorescent intensity was normalised to the untreated samples.  
3.8. Ca2+ measurements in NCI-H716 cells. 
Activation of NCI-H716 cells was assessed by monitoring Ca2+ signals using a flexstation 
plate reader (Multi-Mode Microplate Reader). Protocol was adapted from Le Neve B and H. 
[5] with minor modifications. Briefly, NCI-H716 cells were seeded at 2x105 cells per well in 
a 96 well plate coated with Matrigel for 24 h. Measurement of Ca2+ was achieved after 
loading the cells for 40 min with the membrane-permeant fluorescent indicator FURA-2A. 
Dye loading medium composition was the following: 0.25% Pluronic F-127 and 2μM FURA 
2AM in Krebs buffer pH7.4 (ll mM: 137NaCl, 5.4KCl, 1.2 CaCl2 2H2O;1M gSO44 7H2O; 
0.3 NaH2PO4 H2O; 0.3 KH2PO4; 10 (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES). Test reagents were prepared in Krebs buffer and automatically added onto the cells 
during the assay. Measurements were typically carried out for 350 seconds using Flexstaion 3 
Multi-Mode Microplate Reader. Fluorescence signals were read at excitation 340/380 nm–
emission 510 nm. Ionomycin (INO) 5 μM was used as a positive control in all experiments. 
Each effector was tested in triplicate. 
3.9. Atomic emission spectroscopy (AES) 
Iron content of lactoferrin was determined by Microwave Plasma Atomic Emission 
Spectroscopy (MP-AES). Samples were prepared by dissolving 0.01 g/mL of lactoferrin in 
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Milli Q water. Iron standards ranged from 0-10 ppm from which the standard curve was 
obtained. Three replicates were performed for each sample on an Agilent Technologies 4200 
MP-AES instrument. 
3.10. Synthesis of Apo-LF-polyphenol conjugates 
Apo-LF-EGCG conjugates was synthesized according to Liu et al. (2016) [23], with slight 
modifications in Apo-LF and EGCG concentration. In brief, stock solution of 20 µM of Apo-
LF was prepared by dissolving 0.0016 g/mL in phosphate buffer (PB) at pH 7.0 and stirred 
for 2 h to ensure the sample is fully dissolve. To prepare LF-EGCG conjugates, 1 mM of 
EGCG stock solution was prepared by dissolving 0.0004 g/mL in PB. Both Apo-LF and 
EGCG solutions were mixed to obtain 15.63-500 µM final concentrations of EGCG with a 
constant Apo-LF concentration of 10 µM. The samples were continuously stirred for 24 h at 
RT. Table 3.5 depicts the method of sample preparation used for preparation of the 
conjugates. The samples were dialyzed for 24 h against water to remove free EGCG. 
Thereafter, the resulting solutions were frozen at -80 °C and dried using an OPERON 
(Gimpo, Korea) freeze dryer at -55 °C to obtain powder. 
Table 3.5: Concentration depending on preparation of Apo-LF-EGCG conjugates in PB at pH 7.0 
Final Conc. of 
EGCG (µM) 
Apo-LF 20 µM 
Stock (µL) 
EGCG 1 mM 
stock (µL) 
PB (µL) 
500.00 1500 1500.00 0.00 
250.00 1500 750.00 750.00 
125.00 1500 375.00 1125.00 
62.50 1500 187.50 1312.50 
31.25 1500 93.75 1406.25 
15.62 1500 46.88 1453.12 
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3.11. Characterisation of Apo-LF-polyphenol conjugates 
3.11.1. Fourier Transform Infrared (FTIR) Spectroscopy 
The FTIR spectra of the samples obtained after freeze dryer were measured using a 
GladiATR Single Reflection instrument in the 400−4000 cm-1 range, with a resolution of 4 
cm-1. For each measurement, 20 scans were taken. The samples analysed were free Apo-LF, 
free EGCG, and freeze-dried Apo-LF-EGCG complexes. Data were analysed using OPUS 
Spectroscopy Software version 7.2.139.1294 and Origin software version 16. 
3.11.2. Circular Dichroism (CD) Measurements 
Samples were used in liquid form before the freeze dryer was applied. The CD spectra results 
were recorded using JASCO J-1500 CD (Japan) spectrometer in the far-UV (190−300nm) 
range, under constant nitrogen flush. Path lengths of the cuvette used was 0.1 cm. Ellipticity 
was recorded at a speed of 100 nm/min with 0.1 nm resolution. Each spectrum presented was 
the average of three consecutive measurements. Changes in secondary structure of Apo-LF 
were obtained by online website calculation http://perry.freeshell.org/cgi-bin/raussens.cgi. 
3.11.3. Fluorescence Spectroscopy Measurements 
Hence fluorescence measurements were conducted to determine the mechanism of interaction 
between Apo-LF and EGCG in the conjugates. Fluorescence measurements were carried out 
using a fluorescence spectrophotometer (FluoroMax-4, Horiba). Fluorescence emission 
spectra of Apo-LF were recorded with the excitation wavelength at 285 nm with emission 
from 295-500 nm. Both excitation and emission slit widths were set at 1 nm. The 
fluorescence quenching data were analysed by fitting to the Stern−Volmer equation (eq 1). 
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F0 / F = 1 + Ksv [Q]    (eq:1) 
Where F0 and F refer to the fluorescence intensities in the absence and presence of the 
quencher, and [Q] is the concentration of quencher. Ksv is the Stern−Volmer equation 
constant [24-26]. The binding constant Kq and the number of binding sites n can be calculated 
according to a double-logarithmic equation (eq 2). 
log F0 –F / F = log Kq +  n log[Q]  (eq:2) 
The intercept of the double logarithmic Stern−Volmer plot provides the binding constant 
(Kq), and the slope yields the number of binding sites (n). 
Since the thermodynamic forces responsible for the binding of EGCG to Apo-LF did not 
follow a linear regression, polynomial fit was employed as described by Galaon and David 
[27]. The dependence of lnK on 1/T is represented by the following equation:  
𝒍𝒏𝑲 = 𝛂𝟎 +
𝛂𝟏
𝑻
+
𝛂𝟐
𝑻𝟐
  (eq: 3) 
Where K is the binding constant at the corresponding temperature (T) in Kelvin. 
The thermodynamic parameters can be calculated using the following equations: 
𝚫𝐇° = −𝐑(𝛂𝟏 + 𝟐
𝜶𝟐
𝑻
)           (eq: 4) 
𝚫𝐒° = 𝐑(𝛂𝟎 −
𝜶𝟐
𝑻𝟐
)                  (eq: 5) 
ΔG° = ΔH° - TΔS°                (eq: 6) 
Where R is the gas constant (8.314 J/K mol), ΔH° and ΔS° correspond to the changes in 
enthalpy and entropy, respectively and ΔG° corresponds to the Gibbs free energy. 
3.11.4. Zeta potential 
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The ζ-potential of the complex was determined using a Malvern Zetasizer Nano ZS (Malvern, 
United Kingdom). Samples were loaded in a folded capillary cell and temperature was set at 
25 °C. All samples were dissolved in PB (pH 7.0) to 0.001 g/mL. The data were collected 
over 15 sequential readings. The ζ-potential measurements were reported as the average of 
three measurements. 
3.11.5. Electron microscopic analysis  
Scanning electron microscopy (SEM) was used to study the microstructure of lactoferrin (LF) 
protein before and after its conjugates with EGCG. Freeze dried samples was gently mounted 
on SEM stubs covered with a double-sided carbon tape and sputter coated with a fine layer of 
gold. The microstructure of  LF samples was examined by means of Philips XL30  digital 
scanning electron microscope operated at 30 kV accelerating voltage.   
3.11.6. ABTS•+ radical scavenging activity 
The amount of antioxidant activities in the LF-EGCG complexes were determined using 
ABTS·+ decolouring assay accordingly to Re et al. (1999) [28] with slight modifications. 
First stock solution of 7 mM of ABTS•+ was prepared by dissolving 3.9 mg/mL in water. 
ABTS•+ free radical was produced by reacting ABTS•+ stock solution with 2.45 mM of 
potassium persulfate. The solution was stored in dark at room temperature for 12 – 16 h 
before use. ABTS•+ solution was diluted with PBS, pH 7.4 to an absorbance of 0.70 (±.02) at 
734 nm using Envision Micro plate reader (PerkinElmer, USA). Trolox standards were 
prepared fresh each time in ethanol to final concentrations between 0-15 µM. Appropriate 
solvent blanks were run in each assay.  The reaction mixture of the standard and complexes 
were obtained by mixing 200 µL of ABTS•+ diluted with 20 µL of each sample.  All 
measurements were run in triplicates. The percentage of antioxidant activity of the conjugates 
was calculated using the following formula: 
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ABTS•+ scavenging activity (%) = (AC - AS) / AC × 100                        (eq:7) 
Where AC is the absorbance of the control, and AS is the absorbance of the samples.  
3.11.7.  HPLC-MS Analysis  
The aim of this study was to develop an efficient High-performance liquid chromatography 
(HPLC) method for the measurement of EGCG in Apo-LF-EGCG conjugate supernatant. To 
perform faster analysis, a conventional HPLC-MS system (Agilent Technologies 1200 Series, 
6410 Triple Quad LC/MS) was equipped with a Zorbax Eclipse Plus C18 analytical column 
(2.1 × 50) mm packed with 1.8 μm particles. EGCG standards ranging from 3.90-500 µM 
were prepared in PB. EGCG content in the Apo-LF-EGCG complexes was determined by 
quantifying the EGCG content in the supernatants after centrifuging the complexes at 10,000 
rpm for 10 mins. The mobile phases consisted of 0.1% formic acid in water (A) and 0.1% 
formic acid in methanol (B). The linear gradient elution system was 75% of A and 25% of B 
for 2 min at a flow rate of 0.3 mL/min and temperature maintained at 30 ° C. 
3.11.8. Stability of EGCG  
The effect of different pH on the stability of EGCG was assessed according to 
Radhakrishnan,et al. [29] with slight modification. EGCG was assessed by preparing 12.50 
µM of EGCG dissolved in 1 mL of PB. The pH of EGCG was adjusted using fix amount of 
2M NaOH and HCL solution to achieve the following final pH values (3, 5 and 7). In a Pyrex 
tube open with free exposure to air at RT, EGCG stability assay was applied at different time 
points (T0, T2h, T4h and T24h). An aliquot (1 mL) of the incubation mixture was tested 
using Hitachi F-7000 spectrofluorometer (Hitachi High-Technologies Co.) in a 1 cm quartz 
cell at 20°C. Scan speed was medium at UV of 200 – 500 nm. 
3.12. Statistical analysis  
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The experiments were conducted in triplicate with 3 replicates of each sample. The results 
were presented as the means ± standard deviation. Statistical analysis were conducted using 
one-way ANOVA using Graph Pad Prism version 7. Statistical differences was considered 
significant when p*>0.05, ** >0.005 and ***>0.0005.   
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Chapter 4: Effect of milk proteins on GLP-1 gene expression and 
extracellular release 
4.1. Introduction  
Milk proteins are considered as high quality proteins based on human amino acid 
requirements, digestibility and their bioavailability functions [1]. The two major components 
of milk proteins are casein and whey. Bovine casein comprises of 80% of total milk proteins 
[2-4] and whey protein comprises 20% of total milk proteins [2, 5]. There are two types of 
commercially produced whey proteins, namely, whey protein concentrate (WPC) and whey 
protein isolate (WPI), WPC contains more fat (5-7%), higher lactose content and higher 
concentrations of lactoferrin than WPI [6, 7].  
Casein is a group of phosphoproteins with molecular weight 26,000 to 45,000 (mol. wt.) [2, 
4, 8] and is made of polypeptides known as α, β and ҡ-caseins [8]. Figure 4.1.a illustrates the 
3D structure of casein in milk. All three fraction of casein are similar in size, with a 
molecular weight of 24 kDa and negative charge. However, they differ in their degree of 
unfoldedness of amino acids, hence it has become an interesting protein due to its unique 
unfolded chemical structure [8]. Casein proteins are endowed with unique biological and 
nutritional functions due to its ability to carry a large amount of insoluble calcium phosphate.  
In addition, casein protein contain citrate, minor ions, lipase and enzymes, in addition to 
calcium and phosphate [3]. Casein can be obtained from skim milk by precipitation with 
either acids or rennet [4], whilst whey proteins remain in the supernatant fraction [9]. The 
high phosphate content of casein in milk allows it to associate with calcium ions to form 
calcium phosphate salts and casein complexes [9]. It contains a higher proportion of essential 
amino acid such as histidine, methionine, phenylalanine and valine. It also contains non- 
essential amino acids such as arginine, glutamic acid, proline, serine and tyrosine [10]. 
65 
 
Casein has been characterized as slow protein as a result of delayed gastric emptying and 
takes longer to increase amino acid profile in blood due to the high acidic conditions in the 
stomach compared to whey proteins [2, 11]. 
Whey includes a range of proteins that stay soluble in the serum phase of the milk after 
separation of curd, at pH of 4.6 at 20 °C, during cheese making [4, 12]. Figure 4.1.b shows 
the 3D structure of whey protein. It contains 50% β-Lactglobulin, 20% α-Lactalbumin, 10–15 
% bovine serum albumin and immunoglobulins and 1–2% lactoferrin [2, 5]. Other minor 
whey protein include lactoperoxidase, β-microglobulin, lysozyme, insulin-like growth factor 
and gamma globulins [5]. It is rich in water-soluble vitamins and lactose [4]. 
Caseinomacropeptide, however, is considered as a sweet whey protein even though it is 
derived from к- casein during cheese making [5]. Whey protein contains a higher proportion 
of the branched chain amino acids (BCAA), including leucine, isoleucine and valine in 
comparison to casein [10, 13]. It is considered as a fast protein, as it is digested and absorbed 
faster - within minutes in the intestine and gives a high blood amino acid profile [2, 5, 10, 
13], hence whey is a good source of amino acids and bioactive peptides generated during its 
digestion [2]. 
 
Figure 4.1: 3D structures of (a) casein and (b) whey protein. These images were obtained from RCSB 
Protein Data Bank. 
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Whole casein and whey have been reported to increase the secretion of satiety hormones such 
as glucagon-like peptide-1 (GLP-1), in the gastrointestinal (GI) tract [14-17]. Since studies 
indicate that stimulation of satiety hormones may lead to reduction in food intake and control 
of body weight, consumption of a diet supplemented with milk proteins has been suggested 
as an approach for the prevention and treatment of obesity and metabolic syndrome-related 
diseases. Casein and whey proteins are commonly used in pre and post work-out protein 
shake powders to help with weight loss and building muscle [18]. However, milk proteins are 
made up of various protein fractions and the exact protein component responsible for 
enabling weight loss is not known. This information is essential to provide insights into the 
formulations of more effective dietary supplements and to help with the development of 
better treatments for obesity and weight loss. 
The object of this chapter is to explore which milk proteins or fractions are responsible for 
the regulation of GLP-1. The human intestinal cell line, NCI-H716, is considered a standard 
cell model to study the regulation of GLP-1 in humans [19]. Hence, this cell line was chosen 
to study the effects of various milk proteins and fractions on GLP-1 protein and gene 
expression. 
4.2. Effect of milk proteins (casein and whey) and its fractions on cells 
viability and proliferation 
Referring to Chapter 3 section 3.5, 3-4, 5-dimethylthiazolyl-2-2, 5-diphenyltetrazolium 
bromide (MTT) assay was used to determine cell viability in triplicate culture wells per 
treatment for each of the different concentration of milk proteins and its fractions including α, 
β and κ-casein, whey protein isolate (WPI), whey protein concentrate (WPC), and bovine 
serum albumin (BSA) with concentrations ranged from (0-5% w/v). 
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4.3. Results 
The results (Figure 4.2) show % cell viability of NCI-H716 cells in the presence of milk 
protein at various concentrations (0-5%) over 24 h. The results showed a progressive decline 
in the cell viability as the concentration of milk proteins was increased. These results indicate 
that all milk protein fractions show dose dependent toxicity. Among casein fractions, κ-casein 
(Figure 4.2a) showed a remarkable decrease in cell viability with less than 30% cell viable at 
2.5% concentration and cell viability was decreased as κ-casein concentration was increased 
in compression with other casein fractions (p< 0.0001). On the other hand, β-casein was less 
toxic to cells at >2.5% concentration. (p< 0.0001 ). However, at concentration higher than 3% 
the cell viability was decreased (Figure 4.2a). Similar pattern was observed for α-casein, % 
cell viability was decreased as the concentration of α-casein was increased with ≈ 62% cell 
viability (p< 0.0001) at 2.5% (Figure 4.2a). In contrast, whey protein fractions showed 
toxicity only above 2.5% as no significant (p < 0.05 and p < 0.001) difference in the toxicity 
profiles of the two fractions were noticed (Figure4.2.b). On the other hand, BSA showed the 
least toxicity with 60% viability (p< 0.0001) even at the highest concentration (cell viability 
>57 % with 5% BSA (Figure 4.2c). This toxicity data suggests that casein protein fractions 
are more toxic to cells than whey proteins. The in vitro toxicity of milk proteins on 
mammalian cells has never been reported in published literature. However, Osborne,et al. 
[20] have tested whole milk proteins on CaCo-2 (epithelial cells) and STC-1 (intestinal 
neuroendocrine tumor from mouse) cells, stating no toxicity was observed, however no 
information was provided on the concentrations tested or testing conditions. 
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Figure 4.2: Cell viability after 24 h of treatment of NCI-H716 cells with milk proteins. Cells 1 × 104 were 
incubated for 24 h with Dulbecco's Minimal Eagle's Medium plus 0.2% bovine serum albumin with or 
without one of the treatments (w/v) ranging from 3.13 to 5 mg/mL (0-5 %) ; (a) caseins fractions, (b) whey 
protein fractions and (c) BSA. Milk protein fractions all show dose dependent increase in toxicity with κ 
casein showing the most toxicity. Values are mean ± SD of three replicates perexperiments and *p < 0.05, 
**p < 0.001 and ***p< 0.0001 when compared with the corresponding untreated cells. 
For further understanding of the results obtained from cells viability, the protein content was 
assessed in the various fractions of milk protein at 3.13 to 50 mg/mL (1 to 5%) (Table 3.1). It 
was found that protein content varied between the various milk proteins. These results further 
indicate that despite the protein content of all casein fractions being less than the whey 
protein fractions, they showed higher toxicity to the cells [21]. This result could be caused by 
molecular weights of each milk proteins which might effect their up take by cells. Casein 
fractions are smaller in a molecular weight (24 kDa) in compassion with whey protein which 
has bigger molecular weight of ~40 kDa. 
Table 4.1. Concentration of milk proteins from 1 to 5% w/v 9 Pierce BCA Protein Assay Kit method 
(mg/mL) Protein contents in milk proteins α, β and κ-casein, WPI and WPC from 1 to 5% w/v measured 
by Pierce BCA Protein Assay Kit method (mg/mL).  
Milk Proteins 1% 2% 3% 4% 5% 
α- Casein 0.11 0.23 0.34 0.45 0.57 
β-Casein 0.53 1.05 1.58 2.10 2.63 
κ-Casein 0.61 1.23 1.84 2.46 3.07 
WPI 0.65 1.31 1.96 2.62 3.27 
WPC 0.79 1.58 2.37 3.15 3.94 
 
4.3.1. Effect of casein fractions and whey proteins on GLP-1 gene 
expression  
Cells were exposed to different concentration of milk proteins at sub-toxic concentrations that 
showed at least 60 % cell viability after 24 h exposure (Figure 4.2) Accordingly, cells were 
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cultured in the presence of 10 mg/mL (1%) α and κ-casein, 10 – 40 mg/mL (1-4 %) β-casein, 
10 - 30 mg/mL (1-3 %) WPC, 10 – 30 mg/mL (1-3 %) WPI or 30 mg/ml (3%)  BSA for 18 h. 
The reason for choosing 18 h for GLP-1 gene expression was based on the method in which 
cells secrete and produce hormones. Cells synthesise and store hormones in their cytoplasms 
and releases these as soon as hormone receptors are stimulated. This is followed by activation 
of relevant genes (gene expression) to synthesis more hormones [22]. Hence, shorter time of 
3h was used for protein expression studies (Section 4.4). It has been reported that 18 h is 
ideal time period for GLP-1R receptor to get activate (elongated period of time) [23]. 
Glucose was used as a positive control (+ve) based on the previous studies done by Won 
Young Song,et al. [24]. Quantitative real time polymerase chain reactions (qRT PCR) for 
genes of interest were normalized with β-actin as a housekeep gene.  
β-casein (Figure 4.3.a) showed the greatest increase in GLP-1 gene expression, overall, with 
1.89 fold increase at 1% w/v. Of the casein fractions, it was possible to examine 
concentration dependant effect of β-casein (up to 3% w/v), since α and κ casein could not be 
tested above 1% w/v, due to high levels of toxicity (Figure 4.3a). Of the whey proteins, WPC 
at 2% (Figure 4.3c) showed a significant effect on the expression of GLP-1 (2.3-fold change) 
in comparison to 3% of WPI (1.5 fold change) as shown in Figure 3.3d. BSA did not show 
any significant effect at all concentrations tested (Figure 4.3d). Glucose (100 μM), the 
positive control, showed a two-fold increase in gene expression and this is in agreement with 
the published data [24].  
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Figure 4.3: GLP-1 gene expression in NCI-H716 cells after 18 h of treatment with milk proteins. NCI-
H716 cells (1.5 × 106) were incubated for 24 h with Dulbecco's Minimal Eagle's Medium with the addition 
of 0.2% bovine serum albumin with or without one of the treatments (w/v) ; (a) α and κ-casein, (b) β-
casein (c) whey protein concentrate (WPC) and (d) whey protein isolates (WPI). WPC showed a 
significant effect on the expression of GLP-1 at 20 mg/mL (2%) (2.3 fold change), whereas, WPI showed 
significant fold change in GLP-1 at 30 mg/mL (3%) by >2 fold change. However, BSA did not show any 
significant effect at any of the concentrations. On the other hand, casein fractions, β casein showed 
concentration-dependant increase in GLP-1 expression relative to other casein fractions (α and κ casein). 
P*>0.05. 
While the effects of casein and whey have been previously explored [14, 17, 25], an in vitro 
comparison of casein fractions and whey proteins has not been reported. β-casein at 3% 
contained 1.58 mg/mL of protein and showed three- fold increase in gene expression, 
compared with WPC (2.37 mg/mL) at 2% and WPI (1.96 mg/mL) at 3% which showed 2.3- 
and 1.5-fold increases, respectively in GLP-1 expression. The results of this study indicate 
that casein fractions have a better effect on increasing GLP-1 gene expression than whey 
protein fractions, since they are capable of regulating the expression at a lower concentration.  
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4.3.2. Effect of casein fractions and whey proteins on protein expression of 
GLP-1  
As a preliminary method of identifying changes to intracellular GLP-1 protein expression, 
confocal microscopy and flow cytometry were used. Cells were exposed to concentrations of 
milk proteins that showed significant increase in gene expression for 3h, before fixing and 
staining the cells. BSA was not included since there was no evidence of increase in gene 
expression.  
4.3.3. Fluorescent microscopic analysis  
GLP-1 expression in response to milk protein on NCI-H716 cell was studied using confocal 
microscopy. Hoechst 33342 is a fluorescent dye that binds to DNA in cells forming a 
fluorescent DNA-DAPI complex. Figure 4.4 displays the confocal images obtained 
with/without the test reagents at sub-concentration which showed highest cell viability. 
Nuclear fragmentation and GLP-1 protein were observed at a magnification of 20x with a 
scale of 100 µm. NIS Elements D 4.1 software was used to quantify the green fluorescence 
from the images. Figure 4.4 indicates that all milk proteins show increase in green 
fluorescence in comparison to the untreated cells, which suggests an increase in intracellular 
GLP-1 protein content. The casein fractions showed the greatest effect on intracellular 
protein content and these results reflect the increase in gene expression observed with these 
fractions in comparison with whey protein.  
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 Figure 4.4: Confocal micrographs depicting increase in GLP-1 protein content in NCI-H716 cells. Cells 1 
× 106 were incubated for 2 h with sub-concentrations of milk protein after for 3 h Upper panel is DAPI , 
middle panel is GLP-1 protein and lower panel is marge of DAPI (blue) and GLP-1 (green) protein. Cells 
treated with all milk proteins (caseins fraction and whey protein concentrated (WPC) and whey protein 
isolation (WPI) showed increases in green fluorescence in comparison to the untreated cells. Scale bar 100 
µm. 
4.3.4. Flow cytometry 
Flow cytometry is used to analyse the expression of cell surface as well as intracellular 
molecules. Cells are incubated with antibodies and analysed using the flow cytometer. Flow 
cytometry was performed to further quantify the cellular GLP-1 protein content in response 
to treatment with milk protein fractions. Figure 4.5 depicts the histograms showing shifts in 
intensity between untreated cells and treatments group with milk proteins. As shown in 
Figure 4.5a. Positively stained cell population showed shift in fluorescence intensity to the 
right when cells were treated with milk protein at sub-toxic concentration. The highest shift 
in the fluorescence intensity observed with β-caseins (2.5 fold change) flowed by α-casein 
(1.8 fold change) in comparison to the untreated cell (Figure 4.5e&f respectively). This 
indicates β-casein shows the highest and significant increase in GLP-1 protein levels. 
73 
 
Approximately same increases in fluorescence observed after treatment with ĸ-casein (1.12 
fold change), WPI (1.11 fold change) and WPC (1.17 fold change) in comparison to the 
untreated cells (Figure 4.5 e&f) which indicates an increase in intracellular GLP-1 
concentration. In addition, Figure 4.6 shows the fold change in fluorescent intensity against 
untreated cells.  
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Figure 4.5: Histograms showing GLP-1 protein expression level in NCI-H716 cells following treatment 
with milk proteins . (a) untreated cells, (b) α Casein, (c) β casein, (d) κ casein, (e) WPI and (f) WPC 
Figure 4.6b indicates the normalised fluorescence with respect to the untreated cells. All milk 
proteins shows an increase in GLP-1 intracellular protein levels similar to the confocal 
microscopy results, where the casein fractions showed higher increase in GLP-1 than the 
whey proteins. This was further quantified using ELISA.  
e 
f 
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Figure 4.6: Relative fluorescent intensities obtained from the (a) flow cytometry data and (b) confocal 
micrographs, with respect to the untreated cells and after 3 h treatment with various milk proteins.  
4.3.5.  Quantitative analysis of GLP-1 protein levels 
To quantify the effect of the milk proteins on protein expression of GLP-1 by ELISA, cells 
were incubated for 3 h with the same concentrations used for gene expression studies 
(Section 3.7). Extracellular and intracellular GLP-1 protein levels from cell lysate and cell 
culture medium, are shown in Figures 4.7 a and b, respectively. The casein fractions once 
again showed the greatest increase with κ-casein fraction (1% w/v) showing the most 
significant increase in intracellular GLP-1 levels (1.2 x106 pg/mL) and release of GLP-1 
(16.7 pg/mL) into the surrounding media.  
Interestingly, WPI (3% w/v) showed release of GLP-1 without any significant increases in 
intracellular protein levels or gene expression (Figure 4.3a). This suggests that WPI has a 
burst release of satiety hormones and without any sustained effect on satiety. The positive 
control, glucose also shows an increase in GLP-1, however, the casein fractions had a greater 
effect of intracellular and extracellular release of GLP-1 protein. Our findings are in 
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agreement with previous study by Geraedts, et al. [25], where whole casein showed the most 
pronounced effects on GLP-1 release compared with the whole whey protein.  
 
Figure 4.7: Effects of casein fractions and whey proteins on (a) intracellular GLP-1 levels and (b) GLP-1 
release from the NCl-H716 cells. Cells were incubated for 2 h with α-casein (1%), β-casein (3%), κ-casein 
(1%), WPC (2%) or WPI (3%). Release following cell lysis and in medium was normalized to the total 
GLP-1 content and expressed as x106 pg/mL and pg/mL respectively. Values are means ± SD of three 
replicate experiments.***p< 0.0001 value compared with the corresponding to untreated cells.  
4.4.  Intracellular calcium contributes to GLP-1 secretion mechanism 
To investigate whether cytosolic calcium is involved in GLP-1 secretion induced by 
treatment with milk protein, changes in intracellular calcium of NCI-H716 cells were 
assessed using FlexStation 33 Benchtop Multi-Mode Microplate Reader (Molecular Devices. 
For this, casein fractions, WPC and WPI were used at 1% concentration. Five μM of 
ionomycin (INO) was used as the positive control [19]. Briefly, NCI-H716 cells were seeded 
at 2×105cells/ml in 96-well flat bottom cell culture plates coated with Matrigel for 24 h. 
Measurements were typically carried out for 25min [Ca2+]i after loading the cells with the 
membrane-permeant fluorescent indicator FURA-2A for 40 min. 
We applied a strategy to investigate the mechanisms by which specific milk proteins may 
cause an increase in intracellular calcium in NCI-H716 cells. Calcium ions play an important 
role in a range of cellular activities, including signal transduction pathways that stimulate the 
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release of neurotransmitters from neurons. Increased levels of [Ca2+]i is one of the main 
mechanisms involved in hormone secretion from enteroendocrine cells. 
As shown in Figure 4.8, α and β-caseins fraction were able to increase the intracellular 
calcium [Ca2+]i response in NCI-H716 at 1% in comparison to κ-casein, WPC and WPI. 
While treatments with both WPC and WPI showed a slight increase in Ca2+ intake. The result 
demonstrates that GLP-1 release by casein fractions, might be brought about due to increase 
in calcium channels activity [19, 26]. 
 
Figure 4.8: Effect of casein fractions, WPC and WPI on [Ca2+] in NCI-H716 cells determined using Fura-
2 fluorescence. NCI-H716 cells were seeded at 2×105cells/ml in 96-well flat bottom cell culture plates 
(volume or cells/well) coated with matrigel for 24 h. Measurement was typically carried out for 25min of 
[Ca2+]i after loading the cells with the membrane-permeant fluorescent indicator FURA-2A for 40min.  
Data were expressed as fluorescence ratio resulting from excitation at 340 and 380 nm. α and β-casein 
showed the highest/greatest effect on intracellular signalling of [Ca2+ ] i in NCI-H716 cells compared to κ-
casein, WPC and WPI. 
4.5.  Discussion  
Previous studies have found that proteins and milk proteins shown to increase the regulation 
of GLP-1 hormone in both in vitro and human studies [11, 16, 25, 27, 28]. However, the 
signaling mechanisms underlying these effects are still unknown. 
The results of these studies supported the hypothesis that different milk proteins including α,β 
and κ-casein, WPI and WPC have different effects on GLP-1 secretion. Existing in vitro 
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studies have produced contradictory results on the effect of whole casein and whey proteins 
on the regulation of satiety hormones [16, 25]. The results reported here indicate that casein 
fractions have the most significant effect on the regulating GLP-1 at the gene expression and 
protein secretion levels, as well as on the intracellular free calcium response of NCI-H716. 
There has been a considerable amount of contradiction amongst previous studies that, whey is 
better than casein or vice-versa. A possible reason for the contradictory results in published in 
vitro data could be the use of different cell lines for the studies. One of the studies used  
mouse endocrine cell line STC-1 [25], while the other used the NCI-H716 cells [16]. The 
results of this study are in agreement with the earlier observations that used the same cell line 
[16], in that the whole casein was found to be more efficient at increasing GLP-1 levels than 
whey. 
The effect of milk proteins on cell viability and proliferation were tested after 24 h of 
exposure. The results indicate that all milk proteins showed a dose-dependent increase in the 
toxicity. Among casein fractions, κ-casein showed the most toxicity on % cell viability with 
concentrations above >1% showing less than 30% viability (Figure 4.2a). β-casein was the 
most promising with regards to use as a dietary supplement since α- and κ-caseins showed 
high levels of toxicity to the cells.  
Whey proteins showed less toxicity on cell viability in compression to casein fractions 
(Figure 4.2b&c). Whey protein fractions showed toxicity only at the concentration above 
2.5% with no significant difference in the toxicity profiles of the two fractions (WPC, WPI 
and BSA). In order to explain the toxicity of milk proteins, the protein content of various 
fractions at 1 to 5% was assessed. These results showed that despite the protein content of all 
casein fractions being less than the whey protein fractions, they showed higher cell toxicity.  
This may have been due to the differences in the up-take of different protein caused by 
differences in the molecular weight of casein versus whey proteins. Different casein proteins 
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have lower molecular weight (24 kDa) in comparison to WP (~40 kDa). For instance, κ-
casein showed the greatest increase in GLP-1 gene expression (3.1 fold change) at 1% w/v. β-
casein have showed promising results in the current study, to be used as anti-obesity due to 
its effect on the regulation of GLP-1 hormone. It was possible to obtain concentration 
dependant effect of β-casein (up to 3% w/v), since β-casein exhibited significantly lower 
toxicity  in compression to α and κ. It is noteworthy that  β-casein from non-dairy sources has 
also been shown to exert similar effects when compared with other casein proteins [19, 26]. 
Of the whey proteins, WPC showed a significant effect on the expression of GLP-1 at 2% 
(2.3-fold change) as shown in Figure 4.3a, in comparison to WPI. BSA and WPI did not 
show significant effect at any concentration tested. Glucose (used as positive control), 
showed a 2-fold increase in gene expression and it is in agreement with the published data 
[22]. However, WPI also caused an increase in extracellular GLP-1 release, without an 
increase in intracellular or gene expression of GLP-1. A possible explanation for this could 
be the difference in composition of WPC and WPI; WPC contains higher concentration of 
lactoferrin than WPI [6, 29]. Lactoferrin alone has been shown to increase GLP-1 secretion 
[30] . Lactoferrin in whey proteins may also play a role in satiety regulation. To explore this 
further, the effect of the various forms of lactoferrin on GLP-1 is explored further in Chapter 
5. This also suggests that WPI might not be of significant value as a dietary supplement, since 
it does not support sustained regulation of GLP-1. It should be noted that protein structures 
and composition play a major role in the regulation of satiety hormones. Whey protein is 
considered as a ‘fast protein’ as it is rapidly digested and absorbed and imparts a high blood 
amino acid profile [2, 5, 10, 13]. On the other hand, casein is a ‘slow protein’ since it delays 
gastric emptying [2, 11]. Hence, whey proteins cause a spike in GLP-1, that quickly 
dissipates, while casein allows a prolonged GLP-1 secretion. This is reflected in the results of 
this study, where the casein fractions showed sustained GLP-1 regulation at the protein and 
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gene expression levels. Similar results were reported by Remier R, et al. [19] and Le Nevé 
and Daniel [26] , who showed increased GLP-1 expression with small molecular weight 
proteins such as tetra-glycine, tetra-alanine. 
In conclusion, casein protein fraction show promising effects on the regulation of satiety. 
From the results of this chapter, β-casein showed the greatest effect on the regulation of GLP-
1 with high gene and protein expression and less toxic to cell. 
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Chapter 5: Characterization of milk protein– polyphenols conjugate 
5.1. Introduction 
Fluid, especially water, the largest part of human diet, is essential for cellular homoeostasis 
and life [1]. Beverages are suggested to account for up to 25% of the total daily energy intake 
and as a result are the focus of attention for their potential role in energy intake and body  
weight homeostasis [2]. Their consumption has also been associated with the rise in obesity 
and metabolic diseases [3, 4]. Beverages can be classified into four categories based on their 
impact on body weight: 
i. Alcoholic beverages: are considered as low satiety with low impact on body weight as they 
enhance hunger and decrease fullness ratings and satiation when consumed in moderate 
quantities, especially with meals. The mechanisms for these effects are not yet clear, however 
research suggest that this may relate to aspects of ethanol metabolism or psychoactive 
properties of alcohol.  
ii. Clear beverages: these are considered as low satiety with high impact on body weight [5-
7]. With the increasing popularity of certain types of drinks, especially teas and coffees, 
studies are focusing on their effect on energy balance and body weight. The mechanisms 
behind their effect on body weight might be due to the fluid vehicle than beverage type or 
nutrient composition.  
iii. High viscosity or energy dense drinks are high satiety: these have high impact on body 
weight and are the beverages formulated to have high nutrient density and satiety value. Their 
satiety value mainly comes from protein and fiber content. Examples include pre and post 
workout drinks.  
iv. Soups: these exhibit high satiety and have low impact on body weight. Also, these products 
vary highly in their rheological properties and nutrients content. In short term studies, soups 
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have been shown to provide strong satiation and satiety properties, enhance weight loss and 
assist in the maintenance of reduced body weight.   
According to the US Dietary Guidelines for Americans, milk is considered a high viscosity 
beverage since it has high impact on satiety and body weight [8]. Chapter 4 dealt with the 
effects of milk proteins and fractions on glucagon-like peptide-1 (GLP-1). Based on the 
findings, whey protein concentrate (WPC) has greater effect on the regulation of GLP-1 than 
whey protein isolate (WPI) (Chapter 4 Section 4.6) and this was possibly due to the higher 
concentration of Lactoferrin (LF) in WPC as compared to WPI [9, 10]. Lactoferrin can aid in 
several biological functions such as defence against infections in the gastrointestinal tract, 
modulation of cell growth, immune function and antibacterial properties [11, 12]. It exerts its 
anti- inflammatory effect by inhibiting hydroxyl radical formation and glycosamino-glycans 
[13, 14] 
Lactoferrin (LF) is also known as lactotransferrin. It was first discovered and isolated by 
Sorensen and Sorensen from bovine milk in 1939 as a red protein in whey [15]. LF is found 
in high concentrations in colostrum and milk [15, 16], and can be found in healthy bovine 
milk at concentrations of 1.15 μg/ml  to 485.63 μg/ml [16, 17]. It is a glycoprotein comprised 
of a single polypeptide chain containing 703 amino acids folded into two globular lobes with 
a molecular weight of about 80 kDa. One lobe is called C – (carboxy) and other is N – 
(amino) regions, they are connected with α-helix [16, 18]. It comprises of 33-34% helices and 
17-18% strands and also contains very low quantities of other metal ions like Al3+, Ga3+, 
Mn3+, Co3+, Cu2+, Zn2+ [16]. Figure 5.1 displays the 3D structure of LF.  
It can be classified into three main forms based on the iron content: (1) apolactoferrin (Apo-
LF iron free), (2) monoferric form (mono-LF one ferric ion), and (3) hololactoferrin (holo-LF 
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binds two Fe3+ ions) which has the most compact chemical structure [16, 19]. Due to iron 
binding properties , LF plays an important role in iron uptake by the intestinal mucosa [20].  
 
Figure 5.1: 3D structure of Bovine LF that shows the N and C – lobe. Adopted from Arutyunova,et al. 
[21] 
Tea is a clear beverage that is also known to have a high impact on the body weight. Based 
on the fermentation process, tea is classified into three main types green (unfermented tea), 
black (fully fermented tea), and oolong tea (partially fermented); and the total world 
production of these different types, of tea is 20%, 60% and, 80%, respectively [22, 23]. Tea 
has been found to be rich in polyphenolic compounds, accounting for ~30% of its total dry 
weight [24, 25], which are responsible for numerous health benefits. These compounds can 
be classified into different groups based on either the number of phenol rings or structural 
elements that bind to these phenol rings. The main groups are phenolic acids, flavonoids, 
stilbenes, and lignans [26].  
Green tea, in particular, is a rich source of flavonoids also known as catechins. There are 
many type of those catechins including (+)-catechin (C), (-)-epicatechin (EC), (-) -
epigallocatechin (EGC), (-)-epicatechin gallate (ECG), and (-)-epigallocatechin gallate 
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(EGCG) [23, 25, 27]. Figure 5.2 provides the basic structure of the different types of 
catechins. The catechins are colourless, water soluble compounds that are readily oxidisable 
[28]. Green tea contains more than 50% EGCG which contributes to its health benefits such 
as antioxidant effect, cancer prevention, improving cardiovascular health, enhancing weight 
loss and protecting skin from sun  damage and skin cancer [29-33].  
 
Figure 5.2: Chemical structure of different catechins in tea. Epicatechin: R1=H, R2=H; epigallocatechin: 
R1=OH, R2=H; epicatechin gallate: R1=H, R2=gallate (3,4,5-trihydroxybenzoyl); epigallocatechin 
gallate: R1=OH, R2 = gallate (3,4,5-trihydroxybenzoyl) adopted from [34]. 
Milk is considered as an ideal vehicle for the delivery of bioactive compounds such as 
phenols for targeting modern lifestyle diseases for example diabetes, cardiovascular diseases 
and cancer [35]. Polyphenols, including EGCG have been shown to have a higher impact on 
the regulation of satiety hormones in comparison to sugar, amino acids and fatty acids [36]. 
Hence, the work in this chapter aims to explore the effects of the addition of polyphenols to 
milk proteins, in this case Lactoferrin.  
In this chapter, we are focussing on improving our understanding of protein-phenol 
interactions between LF and EGCG, and their effect on protein functionality, as it is 
important to elucidate the effects of polyphenols on the functional properties of the protein.  
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5.2. Results  
Apo-LF-EGCG conjugates were synthesised with increasing concentrations of EGCG 
(15.625-500 µM) as described in Chapter 3 Section 3.9. Apo-LF was chosen for its higher 
antioxidant properties than mono-LF and holo-LF [37], hence would provide better potential 
as a food supplement. Additionally, Apo-LF has least amount of iron content, therefore when 
investigating the effect of the conjugate there would be least interference from iron. Iron 
content was determined as shown in Chapter 3 Section 3.9, and the effect of iron on cells will 
be dealt with in Chapter 6.     
Figure 5.3 displays the scanning electron microscopy (SEM) images of free Apo-LF and the 
conjugates synthesised with the lowest (15.625 µM) and highest (500 µM) concentrations of 
EGCG. The freeze dried Apo-LF has a smooth surface morphology (Figure 5.3a), compared 
to the conjugates. The surface of Apo-LF becomes more uneven when the EGCG 
concentration is increased (Figure 5.3b and c). These results of SEM micrographs for apo-LF 
match with previous published reports [37, 38]. These changes in structure were further 
investigated to gain deeper understanding. 
 
Figure 5.3: SEM micrographs of (a) freeze dried Apo-LF, (b) Apo-LF with 500 µM of EGCG and (c) Apo-
LF with 15.613 µM of EGCG conjugates.  The surface of Apo-LF became uneven as the concentration of 
EGCG was increased. Scale bar = 2 µm.  
5.2.1. Macular conformation changes in the conjugates  
Fourier transform Infrared (FTIR) spectroscopy was utilised to study change in secondary 
and tertiary structure due to side chain interaction of protein with EGCG [39, 40]. In addition, 
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changes in the EGCG structure were also studied. These changes were analysed using OPUS 
software (version 7.2.139.1294) and resulting graphs with peak annotations are shown in 
Appendix 1.  
EGCG has main peaks around 3550, 3476, and 3355 cm-1, which represent the O−H linkage 
of phenolic and hydroxyl groups (represented by * in Figure 5.4a). It also contains two peaks 
around 1691 and 1616 cm-1 (represented by lines in Figure 5.4b) due to the carbonyl 
stretching of the gallic acid [41, 42] and the region between 900-700 cm-1 (represented by a 
circle in Figure 5.4b) contains peaks unique to EGCG [40, 42]. In the conjugate, it was found 
that at lower concentrations of EGCG (up to 62.50 µM), there was a shift in the 3550, 3476, 
and 3355 cm-1 peaks to lower wavelength. However, these peaks are replaces by a broad 
feature around 3300 cm-1, when the EGCG concentration increases, The peaks at 1691 and 
1616 cm-1 have also shifted to lower wavelengths, accompanied by a disappearance of the 
characteristic peaks between 900-700 cm-1. These changes are due to intermolecular H-bonds 
and O−H stretching modes of the EGCG when conjugated with Apo-LF. This indicates that 
EGCG interacts with the protein through hydrogen bonds at the O-H and carbonyl groups. 
These results are in agreement with previous findings [40, 42]. 
With regards to Apo-LF, the area in the spectra between 2936 and 2875 cm-1 (represented by 
a * in Figure 5.4c) is associated with anti-symmetric and symmetric CH2 stretching vibrations 
of the protein. There is a shift to high wavelength in this region in the case of the conjugates. 
This suggests that hydrophobic interactions are involved [42] in the formation of Apo-LF-
EGCG conjugates. Table 5.1 representing the FTIR spectra for EGCG and Apo-LF after 
conjugation process. 
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Table 5.1: Changes observed in the Apo-LF and EGCG FTIR spectra after conjugation 
Peak Area represented Appearance in 
complex 
Indication References 
Changes in FTIR spectra of EGCG after the conjugation processing 
3550 
3476 
3355 
Vibration of O-H linkage 
of phenolic and hydroxyl 
groups 
Highest concentrations 
of EGECG replaced by 
broad peak at 3300. 
 
Apo-LF-EGCG 
complex 
interaction by 
hydrogen 
bonds. 
Polyphenols is 
bound to 
proteins by H-
bonds. [43, 44]  
1691  
1616 
Carbonyl stretching of the 
gallic acid 
Shifted to lower 
wavelengths 
Confirms Apo-
LF-EGCG 
complex by 
non-covalent 
interaction 
[42] 700-900 Characteristic of EGCG Disappeared 
Changes in FTIR spectra for Apo-LF  protein after the conjugation processing 
2936  
2875 
Antisymmetric and 
symmetric CH2 stretching 
vibrations   
shift to high 
wavelength 
Hydrophobic 
interaction 
[42] 
1392 C-O stretching bond of 
carboxyl groups 
Disappeared 
Indicates 
involvement of 
these groups in 
the LF-EGCG 
complex 
formation. 
1446 Associated with the C−H 
deformation of the protein 
in (R− CH3) 
Shifted to lower 
wavelength in the 
conjugates 
1234 Associated with N−H of 
the amide III band 
shifts to higher 
wavelength with 
higher EGCG 
concentrations 
 
Apo-LF has two peaks at 1392 cm-1 associated with the C−O bond stretching of carboxyl 
groups and 1446 cm-1 associated with the C−H deformation of the protein in (R− CH3) 
(represented by * in Figure 5.4d) which have shifted to lower wavelength in the conjugates.   
 It also has a band at 1234 cm-1 which is associated with N−H of the amide III band [40, 42] 
(line in Figure 5.4d), which is present at lower EGCG concentrations in the conjugates, 
however shifts to higher wavelength with higher EGCG concentrations. These changes to the 
secondary structure are further investigated by circular dichroism (CD) spectroscopy, below. 
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Figure 5.4: FTIR spectra of Apo-LF-EGCG conjugates, where a&b shows the effect of phenols (EGCG) 
on Apo-LF, and c&d show the effect of Apo-LF on EGCG structure at pH 7.0 
5.2.2.  Effect of phenol on the secondary structure of Apo-LF  
Circular dichroism spectroscopy data provides information on α-halix and β-sheet structure in 
proteins [45]. Data analysis found in this study showed that when Apo-LF is conjugated with 
EGCG, there is a decrease in α-helix of Apo-LF with parallel increase in β-sheet (refer to 
Chapter 3 Section 3.11.2). This change in secondary structure increases with increasing 
concentrations of EGCG (Except with 250 µM). These results, together with the FTIR data 
a 
d c 
b 
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reveal that there is a physical interaction between the phenols of EGCG and the Apo-LF 
secondary structure and this is in agreement with previous studies [40, 42, 46]. 
Table 5.2. Secondary structure of Apo-LF, and Apo--EGCG conjugates 
Sample 
Apo-LF 
10µM 
Apo-LF-EGCG conjugates (µM) 
500 
 
250 125 62.50 31.25 15.62 
α helix 31.7 16.0 40.1 18.8 22.2 24.7 28.9 
β strand 13.9 38.8 3.3 27.7 17.2 22.2 18.2 
 
Figure 5.5: Far-UV CD spectra of Apo-LF-EGCG conjugate at 20°C. Conjugates a polyphenol with 
protein is causing a decreased in α-helix of Apo-LF with parallel increase in stand and turn. 
5.2.3. Surface charge   
Previous studies showed that the addition of green tea polyphenols to proteins donot affectthe 
ζ-potential of proteins [47]. However, in this study, we found that the ζ- potential of the Apo-
LF was, in fact, affected by the presence of EGCG. Apo-LF is a basic protein with a high 
isoelectric point (pH 8.5), and the ζ-potential of the Apo-LF was found to be 8.86 mV, where 
this charge was changed in the presence of EGCG to -5.88 mV. Interestingly, the change in 
the ζ-potential of the conjugate with increasing EGCG concentration were not significant 
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(Table 5.3), which would be expected, since FTIR and CD data exhibited a concentration 
dependent change in the secondary structure of Apo-LF. 
Table 5.3: ζ-potential of the conjugate, EGCG and Apo-LF 
EGCG concentration (µM) Zeta potential SD 
500 -7.26 0.33 
250 -6.29 0.02 
125 -6.33 0.33 
62.5 -6.03 0.3 
32.25 -6.29 0.43 
15.162 -5.33 0.10 
EGCG alone (500) -13.23 0.60 
Apo-LF alone 10  8.86 0.50 
5.2.4. Binding parameters  
In general, heating a protein causes conformational changes in both secondary and tertiary 
structures of proteins, which may influence Apo-LF conjugate with EGCG. Aromatic 
residues of tyrosine (Tyr) and tryptophan (Trp) contribute to hydrophobic interactions that 
stabilize the main structure of protein interiors because they have relatively large polar 
surface areas [42, 48]. The tryptophan and tyrosine residues are often found fully or partially 
buried in the hydrophobic region of protein, at the interface between two protein domains or 
subdomains [42, 49]. Hence, measuring changes to the inherent tyrosine and tryptophan 
fluorescence emission spectra will provide information for understanding structural changes 
during the conjugation of Apo-LF with EGCG [42]. It can also provide insight into the 
binding mechanism and thermodynamic parameters involved in the conjugation process [50]. 
The fluorescence of the tyrosine residues in Apo-LF was used for this study and the results 
are shown in Figure 5.6. To optimise the length of time required to solubilise the Apo-LF in 
the phosphate buffer (PB), fluorescence spectra were collected at various time points from 0-
24 h. The florescence reached maximum intensity after 2 h and remained constant up to 24 h 
(Figure 5.6a); hence Apo-LF was dissolved for 2 h before it was used for further 
experimentation.  
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Figure 5.6b indicates a decrease in Tyr fluorescence with increasing EGCG concentrations. 
This implies that there is concentration dependent binding between Apo-LF and EGCG. 
When conjugation occurs, the Tyr emission peak can undergo a blue shift, indicating a 
change in structure towards a hydrophobic environment since the Tyr molecule is buried 
further into the native protein structure. A red shift indicates a chance towards a hydrophilic 
environment, possibly resulting from the unfolding of the protein [51]. In this case, there is an 
obvious red shift in the Apo-LF spectra at 339 nm as the EGCG concentration increases. This 
revealed that there was immediate change in the environment of the tyrosine residues and 
possible chance to the secondary structure of Apo-LF in the presence of EGCG [42, 52]. It 
should be noted that EGCG at the highest concentration used for conjugation did not show 
any fluorescence with the excitation wavelength (285nm) used in this study. This indicates 
that the obsereved spectra is solely from Apo-LF. 
 
 
Figure 5.6: (a) Time dependent fluorescence emission spectra of Apo-LF to optimise solubilisation of Apo-
LF and (b) Concentration dependent effect of EGCG on Apo-LF-EGCG during conjugation. Apo-LF 
concentration is 10 µM. The fluorescence intensities were decreased with increasing of EGCG 
concentrations indicating binding of EGCG with Apo-LF.  
The above quenching can occur through two different mechanisms, namely static quenching 
i.e. ground state complex formation or dynamic quenching i.e collisional quenching. This can 
be determined from temperature dependent fluorescent studies, from which Stern−Volmer 
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plots are obtained and the Stern−Volmer constants (Ksv) determined using equations 1 and 2, 
as described in Chapter 3 Section 3.10.3. Table 5.4 summarizes the results and Figure 5.7a 
shows the Stern−Volmer plots. Only concentrations that fall within the linear range of the 
Stern−Volmer regression curve were used. From Table 5.4, it is evident that the Ksv value for 
Apo-LF-EGCG show a decrease with increase in temperature. This indicates that the 
quenching mechanism is static binding, where the EGCG forms a ground state complex with 
Apo-LF [50]. The fluorescence lifetime of the Tyr molecule is 108 s (τ0) and kq was calculated 
using the formula ksv/τ0 [50]. Since the kq values we obtained are in the order of 1013 M-1 s-1 
(Table 5.3) which is above 1010 M-1 s-1, confirms that the quenching resulted from static more 
than dynamic quenching.  
The double logarithmic regression curves of log [(F0-F)/F] versus log [Q] were plotted for the 
Apo-LF-EGCG conjugates (Figure 5.7a&b), the intercept of which gives K, the binding 
constant. Using this binding constant, the thermodynamic forces responsible for the binding 
of LF protein to EGCG were determined using eq3 in Chapter 3 Section 3.10.3. Where K is 
the binding constant at the corresponding temperature (T) in Kelvin, R is the gas constant, 
ΔH° and ΔS° correspond to the changes in enthalpy and entropy, respectively [50]. The 
Gibbs free energy (ΔG°) was estimated from the equation (eq 6) ΔG° = ΔH° / TΔS° 
As listed in Table 5.4, Apo-LF-EGCG conjugates exhibit positive ΔH° and positive ΔS° 
values. This is indicative of hydrophobic forces [50]. The negative ΔG° also indicates 
spontaneity of the binding of EGCG to Apo-LP during conjugation [50]. The interactions 
between Apo-LF and EGCG are driven by hydrogen bonding between phenolic hydroxyl and 
peptide carbonyl, and hydrophobic interactions between hydrophobic amino acid residues 
and the aromatic rings of the phenols [42, 53-55]. Furthermore, a study using Apo-LF and 
EGCG estimates that the binding of the polyphenols of EGCG to Apo-LF seems to be more 
hydrophobic than hydrophilic [42]. 
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Table 5.4: Stern-volmer constants and thermodynamic parameter for Apo-LF-EGCG conjuagtes 
TEP 
°C 
Kelvin Ksv (x 104 M-1) Kq K (x102 M-1 ) ΔG° 
kJmol-1 
ΔH° 
kJmol-1 
ΔS° Jmol-1K-1 
10  283 3.162 3.16231E+12 22.078 -20.621  
 
4.563 
 
 
 
 
 
 
 
 
3.755E+13 
 
 
 
 
 
 
20  293 3.180 3.18026E+12 29.141 -21.511 
30  303 3.007 3.00745E+12 35.922 -22.4 
40  313 3.032 3.03172E+12 34.635 -23.291 
50  323 2.916 2.91569E+12 25.863 -24.181 
60  333 2.823 2.823E+12 20.705 -25.071 
70 343 2.891 2.89113E+12 17.321 -25.961 
 
Figure 5.7 (a) shows Stern - Volmer of F0/F vs. EGCG as per eq1, fig (b) shows the double logarithmic 
regression curves of log [(F0-F)/F] versus log[Q]. The binding constants (K) for the Apo-LF-EGCG 
conjugates indicate the binding capacity increases as temperature rises. The K values for the complexes 
showed an increasing followed by decreasing with temperature; these results revealed that the 
conjugation of phenolic compounds with proteins might change the net charge of protein molecules, 
which in turn influenced the hydrophilic, hydrophobic and surface properties of the protein.  
5.2.5. Measurement of antioxidants activity of the conjugates    
There are some arguments in relation to the effect of milk on the bio-efficacy of polyphenols 
in tea. It has been found that addition of milk proteins to polyphenols decreased their 
antioxidant capacity [56, 57], while other reports have found no such effect [58-60]. In order 
to quantify the antioxidant activity of the Apo-LF-EGCG conjugate, the Trolox Equivalent 
Antioxidant Capacity (TEAC) (Chapter 3, Section 3.11.6)  method was used, using the 
ABTS•+  decolourisation assay [61]. The antioxidant potential of the conjugates was 
 
b a 
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quantified in reference to Trolox standards. A linear regression curve was prepared using 
different concentrations of Trolox from 0 to 3.84 μm from which the percentage of 
antioxidant activities of EGCG alone and the Apo-LF-EGCG conjugates were calculated in a 
time dependent manner.  
The results (Figure 5.8a) indicate that EGCG shows concentration dependent increase in 
antioxidant activity. There is no significant difference in activity between 0 h and 4 h, 
however there is a significant decrease in activity of EGCG after 24 h. At the higher 
concentrations (250 µM and 500 µM) there is a 20% decrease in activity after 24 h. It is 
possible that after 24 h there is a significant degradation that affects the antioxidant activity 
of EGCG. After 24 h dialysis, some free EGCG is either lost or further degraded, leading to a 
significant decrease in the antioxidant activity.  
Figure 5.8b indicates that the Apo-LF-EGCG conjugate has the same antioxidant profile up to 
24 h, as free EGCG. This suggests that the antioxidant properties of the conjugates are from 
EGCG alone, as free LF shows no antioxidant potential. While studies show that LF does (> 
1M) have antioxidant properties [11, 18, 62], the concentration of LF used in this study (10 
µM) was much lower and hence showed no effect. The results also indicate that the EGCG 
antioxidant properties are not hampered during the conjugation process. Interestingly, after 
dialysis (24 WD), the conjugates show the same development as before dialysis (24 ND) and 
this was significantly better than the antioxidant activity of the free EGCG. This suggests that 
the EGCG is firmly bound to the LF structure and protected from degradation and the dialysis 
process, since no EGCG was lost. Similar preservation of green tea polyphenol antioxidant 
activity by milk proteins has been previously reported [33, 56, 63], however, none of these 
studies have shown this behaviour with Apo-LF-EGCG conjugates. 
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Figure 5.8: Time dependent antioxidant activity of (a) EGCG alone and (b) Apo-LFP-EGCG conjugate at 
time 0 h, 4 h, 24 h with no dialysis (ND) and 48 h with dialysis (WD) using ABTS•+ decolourisation assay 
Apo-LF-EGCG complex shows better antioxidant activity after 24 hours in comparison to free EGCG. * 
< 0.05, **< 0.001 and ***<0.0001 in comparison to 0 h. +++<0.0001 in comparison to the corresponding 
concentration of free EGCG.  
5.2.6. Estimation of phenol content in the conjugates 
The aim of this study was to determine the amount of EGCG associated with Apo-LF in the 
conjugates. This was achieved by centrifuging the conjugates after synthesis, followed by 
HPLC-MS analysis of the supernatants to quantify the free EGCG not involved in the 
conjugation process. The results (Table 5.5) is displayed as percentage of EGCG in the 
supernatants, calculated with respect to the initial concentrations of EGCG used for synthesis. 
Less than 1% of EGCG remained in the supernatant, indicating ~99% of EGCG is bound to 
Apo-LF during the formation of the conjugates. This suggests that, as EGCG concentration 
increases, the amount of EGCG in the conjugates also increases. The antioxidant activity 
results (Section 5.2.5) support this finding. This further suggests that the phenols were 
protected by the protein.  
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Table 5.5: Percentage of EGCG found in supernatant of Apo-LF-EGCG complex 
EGCG concentration in 
complexes (µM) 
% EGCG in 
supernatant 
500 0.96 
250 0.41 
125 0.10 
62.5 0.10 
31.25 0.04 
15.625 0.07 
 
5.3. Discussion 
Several studies have shown strong interactions between polyphenol in green tea, such as 
EGCG, EGC and gallic acid (GA) with milk proteins [13, 14, 64]. However, these studies 
have focused on milk protein-polyphenols interactions and not on the formation of 
conjugates. This study demonstrated a successful and effective conjugation between milk 
protein (Apo-LF) and EGCG. It also confirms that Apo-LF has the potential to be used as a 
platform for delivery of polyphenols. Proteins are widely used in food applications because of 
their functional attributes and nutritional value [65]. In particular, LF plays a vital role in 
human health through antimicrobial activities and defence against infection and inflammation 
in the gastrointestinal tract. Hence, LF is used in food supplements, functional foods and 
therapeutic drinks. Proteins–polyphenol conjugates, on the other hand, have their own 
speciﬁc functional attributes and formation of Apo-LF-EGCG conjugates leads to the 
development of a new ingredient with novel functional properties.  
Protein-polyphenol interactions are based on two main mechanisms, either through the 
hydrogen bonding between hydroxyl group in the phenol and peptide carbonyl of the protein, 
or hydrophobic interactions between hydrophobic amino acid residues and the aromatic rings 
of the phenols [66-68]. This study revealed that the Apo-LF-EGCG interactions occurred 
through both the above mentioned mechanisms and resulted in associated changes to the 
secondary structure of the protein. 
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The interaction occurs through static binding with hydrophobic interactions. Furthermore, the 
hydrophobicity of the milk protein was decreased in the presence of EGCG and this is 
consistent with earlier reports [69, 70]. Approximately 99% of the EGCG interacts with the 
protein, and the antioxidant properties of the EGCG are protected by the protein. The EGCG, 
in turn, brings the protein into a more hydrophilic environment; hence these Apo-LF-EGCG 
conjugates can be applied in beverages and liquid foods. It is possible that the conjugate may 
protect degradation of LF by pepsin in the stomach, thereby allowing the delivery to the 
intestine in its original form [71]. The protein conformational analysis data shown in Figure 
5.5 indicates that the addition of EGCG causes changes in the secondary structure of Apo-LF 
protein similar to a previous report [72]. This suggests that there is successful interaction 
between Apo-LF and EGCG, with possible changes to the secondary structure of the Apo-LF 
molecule. 
Simultaneously, EGCG is protected from degradation and the antioxidant activity is 
maintained for a longer duration. Since this conjugate shows potential as a dietary 
supplement, the effect of this conjugate on intestinal cells and section of satiety hormone, 
glucagon-like peptide-1 (GLP-1) is investigated in Chapter 6. 
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Chapter 6: Effect of lactoferrin, polyphenols and Apo-LF-EGCG 
conjugates on GLP-1 expression 
6.1.  Introduction  
Previous studies and reviews have shown that non-nutrients have ability to induce the 
secretion of satiety hormones.  Neve, et al. (2010), found that the steroid glycoside H.g.-12 
from Hoodia gordonii plant induces CCK secretion from HuTu-80 cells, and plant-derived 
components are associated with loss of body weight [1]. Capsaicin, the main pungent 
compound in red peppers, has also been found to increase the secretion of GLP-1 in human 
plasma [2].  
Milk is an ideal vehicle for the delivery of bioactive compounds such as polyphenols and can 
be exploited for targeting modern lifestyle diseases such as cancer and cardiovascular disease 
[3]. Hence, in chapter 5, the ability of milk protein lactoferrin (LF) conjugated with 
epigallocatechin gallate (EGCG) from green tea was investigated.   
As showed in chapter 3, milk proteins show dose-dependent effect on regulation of glucagon-
like peptide-1 (GLP-1) to varying degrees. In addition, a human study performed by Hursel 
and Westerterp-Plantenga [4] showed that protein combined with green tea can help with 
weight maintenance in moderately obese subjects [4]. These effects were linked with 
thermogenesis, fat oxidation, and increases in energy expenditure. Furthermore, study done 
by Stojadinovic,et al. [5] suggested healthy protein-phenol formulation provides beneficial 
effects on human health in prevention of cardiovascular disease and cancer. They also 
considered proteins as  good carriers to carry  phenols in the gastrointestinal track [5]. 
However, there is no study that shows the effect of a LF-EGCG conjugates on the regulation 
of satiety hormones and if it can be used as an anti–obesity formulation. Therefore, this study 
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was planned to investigate the ability of LF-EGCG conjugate on the release of GLP-1 
hormone, in comparison to the individual components. It is important to determine whether 
these ingredients (tea and milk proteins) will work synergistically and are non-toxic to the 
intestinal cells. 
In this chapter, there is an investigation of the possible effect of individual components of 
lactoferrin protein (apolactoferrin (Apo-LF), hololactoferrin, monoferric lactoferrin and 
Epigallocatechin gallate (EGCG) phenol individually and when Apo-LF combined with 
EGCG forming a conjugation with EGCG concentrations ranged between 15.63 to 500 µM 
and a constant concentration of Apo-LF of 10 µM ..  
6.2. Effect of LF protein, EGCG and Apo-Lf-EGCG conjugates on cells 
viability and proliferation 
The main focus of this study was to access the effects of LF proteins including apolactoferrin 
holo-LF, monoferric and hololactoferrin, EGCG, iron chloride hexahydrate and the Apo-LF-
EGCG conjugates on the proliferation of human colon cells (NCI-H716) using 3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay over a period of  24 h. 
LF protein concentrations used ranged between 3.13 to 50 mg/mL (1 to 5 % (w/v)), to 
replicate the concentrations found in milk. Various studies have observed that polyphenols 
inhibit tumorigenesis and proliferation in different cell lines [6-8]. The concentration of 
EGCG were determined based on a similar study conducted by Won Young Song,et al. [9] 
and ranged from 0.63 to 10 mg/mL (0-200 µM). EGCG showed toxic effects on the cells for 
all concentrations above 5 mg/mL (Figure 6.1a). Iron plays an essential role in growth and 
developments of organisms. However, iron also can be toxic for organisms if it is in excess 
[10]. 
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Figure 6.1: Cell viability of NCI-H716 cell after 24 h of treatment with (a) EGCG, (b) iron chloride 
hexahydrate (FeCl36H2O) (c) lactoferrin (LF) include apolactoferrin (Apo-LF), monoferric (mono-LF) 
and hololactoferrin (holo-LF) and (d) Apo-LF-EGCG conjugate. LF samples at concentration below 50 
mg/mL. Whereas, 200 µM of EGCG showed toxicity to cells, Apo-LF-EGCG conjugates showed toxicity 
effect on cell growth at concentration > 0.25mg /mL of each conjugate. Results are the average of three 
independent experiments and bars represent the standard deviation. *p < 0.05, **p < 0.001 and **p< 
0.0001 when compared with the corresponding untreated cells. 
With regards to iron toxicity, Suhr-Jessen and Rasmussen [11] have shown that Fe 
concentrations > 4 µM can be toxic to Tetrahymena thermophile, a eukaryotic cell that has a 
similar metabolism to that of mammalian cells. Therefore, iron content of lactoferrin samples 
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was determined using MP-AES and the concentration of iron were found to be ≤ 0.56 µM, 
1.97 µM and 20.23 µM in Apo-LFand holo-LF (20.23 µM), respectively. Hence, to 
determine the effect of the iron in the LF samples, the effect of FeCl3 was tested in a range of 
0.01 to 0.001 mg/mL concentration, and found to be toxic at ≥0.003 mg/mL (Figure 6.1b). 
There are no published reports that have considered toxicity of these two components on 
NCI-H716 cell line.  
The results (Figure 6.1c) indicate that LF proteins shows dose dependent toxicity to NCI-
H716 cell. Cell proliferation was not drastically affected (~70% viability) with any of the LF 
samples up to 25 mg/mL, above 50 mg/mL cell viability was dropped. Apo-LF is proven to 
act as a growth factor [12], hence no toxicity was expected.  
With regards to the Apo-LF-EGCG conjugate, toxic effect on cell growth after 24 h was 
determined and results shown in Figure 6.1d. Surprisingly, the viability of the cells decreased 
as the amount of EGCG in conjugate decreased. One possible explanation for this effect is 
that EGCG molecule is much smaller than LF; therefore, EGCG might be inserted into the LF 
molecule at high concentration and surround the LF molecule surface at low concentration as 
shown in Figure 6.2.[13]. At higher concentrations ≥250 µM of EGCG, there was less effect 
on proliferation since the EGCG was contained within the LF structure. 
Figure 6.2. Schematic diagram showing predicted Apo-LF-EGCG conjugate and its interaction created 
by Swissdock (a web service) 
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6.3. Effect of LF proteins, EGCG and Apo-LF-EGCG conjugate on 
regulation of GLP-1 gene expression 
Figure 6.3 shows the effect of sub-toxic concentrations of Apo-LF, mono-LF, holo-LF 
proteins and EGCG individually and of Apo-LF-EGCG conjugate, on the regulation of 
satiety hormone after 18 h (refer to Chapter 4.3). Glucose was used as a positive control (+ve) 
[9]. When comparing Apo-LF, holo-LF and mono-LF, 10 mg/mL of holo-LF showed the 
greatest increase in GLP-1 gene expression (2.1 fold) compared to the same concentration of 
Apo-LF and mono-LF (Figure 6.3 a). Apo-LF also significantly enhanced GLP-1 hormone 
expression (1.68 fold) at 30 mg/mL, whereas holo-LF showed higher fold change at 10 
mg/mL (2.1 fold). There is an apparent decrease in GLP-1 expression at 30 mg/mL holo-LF, 
however it showed toxicity at this concentration (Figure 6.3 c). Similar effect of LF on the 
regulation of GLP-1 levels have been reported in an animal study by Yuta Maekawa,et al. 
[14]. However, their study did not include different forms of LF (level of iron saturation). 
Figure 6.3: Effects of (a) lactoferrin, (b) EGCG and Apo-LF-EGCG conjugate on GLP-1 expression after 
18 h of treatment. Cells were treated with test reagent, which show less toxicity effect on cells. Values are 
means ± SD of three replicate experiments. *P>0.05 
* 
* 
* 
* * 
* 
* 
* * 
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Apo-LF-EGCG conjugated with 125 µM of EGCG showed the highest effect on the 
expression of GLP-1 i.e. 2.9 fold increases as compared to 1.8 and 1.35 fold increases at 250 
and 500 µM of EGCG in conjugate, respectively (Figure 6.3b).  
Apo-LF-EGCG conjugate showed increase in cell death as EGCG concentration was 
decreased. This result can be explained by the different molecule sizes between Apo-LF and 
EGCG as referred in section 6.2 [13].  EGCG (5 mg/mL) significantly induced GLP-1 
expression (1.9 fold). These results are in agreement with a previous study done by  Won 
Young Song, et al. [9] who  reported that EGCG polyphenol conjugate can stimulate 
secretion of satiety hormones in Caco-2 cells.   
Interestingly, iron, at a concentration of 0.0013 mg/mL also showed 1.7 fold changes in GLP-
1 gene expression. This effect has not been previously reported. This suggests that the iron in 
LF could contribute to the increased expression of satiety hormones.  
6.4. Study the effect of LF proteins, EGCG and Apo-LF-EGCG conjugate 
on GLP-1 release  
Lactoferrin, EGCG and Apo-LF-EGCG concentrations were selected based on their ability to 
significantly up-regulate GLP-1gene expression as shown in Figure 6.4. Effect of LF, 
including Apo-LF (30 mg/mL), holo-LF (10 mg/mL), EGCG (5 mg/mL) and Apo-LF-EGCG 
conjugate containing 125 µM EGCG were used to determine GLP-1 hormone levels using an 
ELISA assay, due to its effect on increases of GLP-1 gene expression as compared to 250 and 
500 µM EGCG. Cells (2×106) were exposed to test reagents and incubated at 37 ̊ C for 2 h. 
Secretion of GLP-1 into cells culture medium and on cell lysis were expressed as pg/mL. 
Milk protein, phenol and protein-phenol conjugate enhanced GLP-1 release in both 
supernatants following cell lysis (Figure 6.4). 
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Figures 6.4a-b shows the effect lactoferrin, EGCG and Apo-LF-EGCG conjugate on (a) intracellular 
GLP-1 and (b) GLP-1 released in medium after 2 h treatment. Cells were exposed to Apo-LF (30 mg/mL), 
holo-LF (10 mg/mL), EGCG (5 mg/mL) and 125 µM of Apo-LF-EGCG conjugate 0.0125 mg/mL. Values 
are means ± SEMs of four independent experiments. **p < 0.001 and ***p< 0.0001 when compared to 
corresponding to untreated cells. 
When GLP-1concetrations in cell lysate was determined after treatment with EGCG, Apo-LF 
and holo-LF, there was significantly increase in comparison to the untreated (UNT) (Figure 
6.5a), with Apo-LF showing marginally higher increase (3.61times) than holo-LF (3 times, 
Figure 6.4b). The positive control showed 2.65 times higher increase than untreated cells. 
EGCG also showed 18.9 times higher increase compared to untreated cells. With regards to 
the conjugate, there was a significant (~27 times) increase in GLP-1 levels compared with the 
cell lysates from untreated cells. When compared with free Apo-LF and EGCG, the conjugate 
showed 1.25 times and 1.3 times greater increases, respectively. 
Apart from intracellular protein content, the extracellular release of GLP-1 into the 
surrounding cell media was also assessed. This is an important parameter to consider when 
observing hormone regulation, since evidence suggests that a cell can store certain quantity of 
protein in its cytoplasms. This is released in a ‘burst’ when receptors are activated. This is 
followed by increase in gene expression to replenish the cytoplasmic stores of the hormone 
[15]. Most studies only consider the extracellular release of satiety hormones, which only 
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provides information on the “burst’ release, and does not consider gene and intracellular, 
sustained up-regulation of these hormones. Therefore, these studies provide information on 
short-term satiety regulation and do not consider long-term, sustained increase in satiety 
regulation.   
The results from the extracellular release of GLP-1 (Figure 6.4b) showed that Apo-LF, holo-
LF and EGCG increase GLP-1 release in comparison to untreated cells and is similar in trend 
to that observed for intracellular GLP-1 content. While the release of GLP-1 by the Apo-LF-
EGCG conjugate was greater than untreated cells, there was no significant difference when 
compared to Apo-LF.  
6.5. Discussion 
As discussed in Chapter 4 Section 4.2, different milk protein affect differently on cell 
viability and proliferation. The effect of lactoferrin protein samples, EGCG, and Apo-LF-
EGCG on cells viability and proliferation were tested after 24 h of exposure. The results 
indicate that all lactoferrin proteins, EGCG and iron chloride hexahydrate showed a dose-
dependent increase in toxicity. However, in case of Apo-LF-EGCG conjugates, cells viability 
was decreased when EGCG concentration was decreased as well. As discussed in Chapter 5, 
the changes in the secondary structure of the protein increase with increasing EGCG 
concentrations. The protein conformational analysis based on CD data showed that when 
EGCG is conjugated with Apo-LF causes a decrease in α-helix of Apo-LF protein with 
increase in β sheet (Table 5.2). In addition, Figure 5.6.b also shows a decrease in tyrosine 
(Tyr) fluorescence with increasing EGCG concentrations which means there is concentration 
dependent binding between Apo-LF and EGCG. This could indicate that at lower 
concentrations, EGCG sits on the surface of the LF structure, hence not in the vicinity of 
many tyrosine molecules. However as the concentration increases, the EGCG gets imbedded 
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further into the protein, thereby coming in contact and interacting with more tyrosine 
molecules, leading to a decrease in the tyrosine emission spectra. At the same time at high 
concentration of EGCG for conjugation there was no fluorescence with the excitation 
wavelength (285 nm) used. This indicates that the spectra observed are solely from Apo-LF. 
Therefore, when lower concentrations (≤125 µM) of EGCG were used in the conjugate, there 
was a significant cell death. 
From these studies, we found that lactoferrin in its all three forms (Apo-LF, mono-LF and 
holo-LF) has a potential impact on the regulation and release of GLP-1 hormone. 
Additionally, we demonstrated that protein-polyphenol conjugate has greater effect on gene 
and protein expression of GLP-1 in comparison to the LF and EGCG, individually. In 
addition, as it has been discussed in Chapter 4, each milk protein has different effect on gene 
and protein expression of GLP-1, whereas β-casein shows the greatest impact. Similarly, the 
effect of the different types of LF was assessed. Interestingly, holo-LF (20 mg/mL) showed 
significant increase in the release of GLP-1 in intracellular protein levels (Figure 6.4.a) and 
gene expression with less effect in extracellular protein concentration levels (Figure 6.4b) in 
comparison with Apo-LF (30 mg/mL). As discussed in Section 4.3 with regards to the ‘burst’ 
release mechanisms for GLP1, Apo-LF showed (Figure 6.4.a) higher intracellular gene 
expression but a lower increase in extracellular levels of GLP-1.  
The polyphenol EGCG showed effects on the intracellular as well as extracellular protein 
levels (Figure 6.4a&b). As data suggests that the release of GLP-1 from the cells is largely 
governed by the Apo-LF content of Apo-LF-EGCG conjugate. However, the conjugate had a 
greater effect on interacellular GLP-1 production, as well as on gene expression. This would 
suggest that the conjugate not only causes a burst release of GLP-1 hormone, but also has a 
higher potential to induce sustained satiety, than Apo-LF and EGCG. These results are in 
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agreement with Won Young Song, et al. [9] and G. Aktas,et al. [16], who reported EGCG 
induces GLP-1 and Cholecystokinin (CKK) hormones release in another cell line.  
Previous studies suggested iron deficiency and obesity are molecularly linked and equally 
affect each other [17, 18]. Obesity may increase the chances of iron deficiency by reducing 
absorbance of iron from the duodenum [18]. Won Young Song, et al. [9] and G. Aktas, et al. 
[16], reported a relationship between iron deficiency and waist circumference, body weight 
and body mass index (BMI), where people with high body weight and BMI have low iron 
levels. Additionally, the body weights of twenty-one women were significantly reduced when 
treated with oral iron supplement [16, 18]. Hence the use of iron supplements can aid in body 
weight control. Since lactoferrin protein contains iron within its structure, it has been shown 
to aid in iron uptake from the gastrointestinal tract. Therefore, protein-phenol conjugate could 
be a new approach to treat and prevent obesity by its effect on the regulation of satiety 
hormones. Thus, this LF-EGCG conjugate can potentially be used to not only enhance satiety 
and prevent body weight gain, but also as a method of simultaneously treating iron deficiency 
resulting from obesity. 
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Chapter 7: Summary and future direction 
7.1. Summary  
Obesity is considered as an epidemic disease and it has increased dramatically in last few 
years according to World Health Organization (WHO). Increasing body weight leads to 
increase risk of associated disorder diseases such as type 2 diabetes, cardiovascular 
disease and the metabolic syndrome [1-4]. The first strategy to prevent obesity and 
control body weight is to increase energy expenditure and decrease energy intake with a 
sufficient physical exercise. Also, current dietary recommendations and strategies used to 
treat and prevent obesity, mainly focus on the energy density and fat content in the diet 
[5].         
Proteins especially proteins from milk including casein and whey proteins have been 
showed more effect on the satiety and satiation more than fat and carbohydrate by 
increasing the release of satiety hormones such as glucagon-like peptide-1 (GLP-1), 
peptide YY (PYY) and cholesystokinin (CCK) [6-11]. In addition, increasing the 
consumption of dairy proteins have suggested to be a new way to prevent and treat 
obesity, due to their effect on regulation of satiety hormone such as glucagon-like 
peptide-1(GLP-1) and cholecystokinin (CCK) [7, 12, 13]. Nevertheless, there are a 
limited number of studies that has been done in demonstrating the utility of GLP-1 as 
anti-obesity agent, and the importance of enhancing GLP-1 levels for obesity treatment 
[14]. In addition to that,  researchers suggest that increasing GLP-1 could be one of the 
therapeutic approaches for type 2 diabetes, since GLP-1 levels are lower in people with 
Type 2 diabetes [14, 15], and improves insulin release which leads to lower glycerine 
[14]. 
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In milk, casein and whey are the main protein found in dairy products which accounts for 
around 3% of total milk, and contains higher concentrations of essential and non-essential 
amino acids than other protein sources, hence has a high nutritional value [16, 17]. In 
previous studies, milk proteins have been shown to suppress short-term food intake, 
enhance satiety through the stimulation of satiety hormones, therefore lowers body 
weight and decrease risk of developing hyperglycemia and diabetes [4, 12, 18-21]. 
However, inconsistent data exists from different studies to specify which dairy protein or 
fraction has more effect on satiety [9, 18, 19, 21-25].  
The main aim of this thesis was to understand which milk protein and its fraction have 
most impact on appetite and food intake and their effect on the regulation of GLP-1 
hormone. We found that each of the milk protein and its fraction has different effect on 
the regulation of GLP-1 hormone which was confirmed by gene expression through the 
quantitative real-time polymerase chain reaction (qRT-PCR) and protein expression using 
the enzyme-linked immunosorbent assay (ELISA) in vitro studies using human 
adenocarcinoma of the colon cell line (NCI-H716).  
The results of qRT-PCR and ELISA studies indicate that different milk proteins, viz. 
casein fractions (α,β and κ), whey protein concentrate (WPC), whey protein isolate 
(WPI), lactoferrin (LF) protein including apolactoferrin (Apo-LF), monoferric (mono-LF) 
and hololactoferrin (holo-LF) have different impact on the GLP-1 gene and protein 
expression on human colorectal (NCI-H716) cells. β-casein protein had the greatest effect 
on the regulation of GLP-1 hormone compared with other protein, whereas, no effect was 
noticed with mono-LF and bovine serum albumin (BSA). However, other milk protein 
fractions including α and κ casein, WPC, Apo-LF and holo-LF also show increase in 
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regulation of GLP-1 in both gene and protein expression, but not as much as  β-casein. 
WPI, on the other hand, caused an increase in extracellular GLP-1 release, but no 
increase in intracellular or gene expression. Thus, these results suggest that each milk 
protein and fraction would affect differently in short and long term GLP-1 regulation. 
Hence, would have different application in body weight control.     
Milk has been considered as one of ideal vehicle to deliver bioactive compounds such as 
polyphenols [26]. Therefore, protein-phenol interactions become a new area to 
investigate and improve our knowledge in different fields such as medicine, toxicology, 
chemistry and food science. This project focused on the possible use of milk protein-
phenol interaction using Apo-LF and epigallocatechin gallate (EGCG) at different 
concentrations of EGCG with constant Apo-LF concentration to regulate appetite by 
stimulating the secretion of GLP-1. The results (as showed in Chapter 5 section 5.2.1) of 
Apo-LF-EGCG is based on two main chemical reactions (1) hydrogen bonding between 
hydroxyl group of the phenol and the carbonyl group of the peptide and (2) hydrophobic 
interactions between the amino acid residues and the aromatic rings of the phenols [27-
29]. It was also found that addition of milk proteins to polyphenols prevented degradation 
of the phenol and the antioxidant effect of the phenol was maintained. This suggests that 
the EGCG was protected by the Apo-LF protein up to 48h as it showed higher 
antioxidant activity in the conjugate than free EGCG.  
The toxicity studies of the conjugate revealed a positive relationship between increasing 
EGCG concentration and cell viability. The viability of the cells decreased as the amount 
of EGCG in the conjugate decreased. The speculation on the factors that may contribute 
to this trend in toxicity with the conjugate include (i) EGCG molecule is much smaller 
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than Apo-LF, therefore EGCG might be inserted into the Apo-LF molecule at high 
concentration and surround the Apo-LF molecule surface at low concentration, (ii) the 
changes in the secondary structure of the protein increase with increasing EGCG 
concentrations. This could change the conformation of the protein, such that the EGCG at 
higher concentrations are moved towards the center of the protein structure.  
Also, the hypothesis that protein-phenol conjugates have the ability to regulate GLP-1 
genes and protein expression was tested by studying the effect of the Apo-LF-EGCG 
conjugates on GLP-1. Apo-LF-EGCG conjugates show significant effect on enhancing 
the expression of GLP-1 at gene and protein level, more than the individual components 
at equivalent concentrations.  
This research helps to increase our knowledge of the role of milk protein and phenol as 
anti-obesity approach. It will bring an understanding to the importance of milk and its 
proteins in human daily diet and health, which may lead to a decrease in chronic disease 
rates, and increase in a healthier population. In vitro studies of milk proteins and other 
sources of proteins will provide the foundation for meaningful intervention studies. 
Furthermore, the results of this research may lead to increased consumption of milk 
protein by healthy individuals of various age groups in general, and by overweight and 
obese individuals in particular. This research adds to the accumulating evidence that milk 
has potential usage as anti-obesity and provides encouragement to combined milk with 
other beverages especially tea. 
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7.2. Future direction  
Due to an increasing in obesity rate in the last years, there is more motivation for 
developing the developing of the anti-obesity beverages, which have an impact primaril 
on satiety hormone such as GLP-1 and thereby reduce energy intake. This research 
provided biological and food technology explanations for the role of milk protein and its 
fractions on the regulation of satiety hormone, which might work as anti-obesity 
approach. Thus, the results add some biological information and inverse associations 
found between milk proteins and satiety hormone. However, in depth research is required 
in many areas, some of which have been listed below:  
 This project focused on GLP-1 hormone and studies focusing on other satiety regulating 
hormones are required to fully understand the anti-obesity potential of the conjugate used 
in this project. In vivo effects should also be considered, since this project was limited to 
in vitro investigations. 
 As discussed in Chapter 6, the conjugation of lactoferrin with the polyphenols (EGCG) 
from green tea showed better effect on the regulation of GLP-1 than individual 
components. Further is investigation needed to study the conjugation of different milk 
proteins with different polyphenols and investigate their in vitro and in vivo regulation of 
satiety hormones.  
 The concentrations of macronutrients in whole milk differ from those in low-fat and 
reduced-fat milks. Therefore, studies should consider and investigate the effects of 
different types of milk on regulation of satiety hormones.  
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 Protein will digest in stomach by the acidic gastric juices; in vitro assays that stimulate 
the gastric juices should be performed. This will help to understand if the hydrolyzed 
forms of those proteins can also regulate the satiety hormones.    
 A follow-up study assessing the effect of milk protein on insulin production  should be 
a priority in future research as previous studies show the relationship between the satiety 
hormone especially GLP-1 and insulin production in human body [30]. More 
investigations needed on lactoferrin conjugated with polyphenols and using it as iron 
supplement to increase iron absorption and antioxidant effect.  
 Polyphenols, such as EGCG show anticancer properties [31]. However, they can 
degrade quickly in the digestive system [32]. Hence, it might be worthwhile to study the 
effect of milk protein-phenols conjugates for anti-cancer properties, since the results from 
this project suggests that protein can protect the polyphenol from degradation (Chapter 5, 
Section 5.1.5).  
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